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treat them w ith the respect and compassion they deserve: as their lives are 
shortened th a t ours may be prolonged. They cannot even understand.
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ABSTRACT
The interaction of hyperinsulinemia, the sympathetic nervous system 
(SNS) and nitric oxide (NO) was examined in lean and obese unilaterally 
lumbar sympathectomized dogs. Six lean and six obese dogs were studied 
while on a treadmill, during hyperinsulinémie euglycemic clamp (HIEC) 
procedures with and without concurrent nitric oxide synthase (NOS) 
inhibition w ith nitro-L-arginine (LNA). Changes in plasma insulin, femoral 
vascular resistance (FVR), heart rate (HR) and mean arterial pressure 
(MAP) were measured prior to and during a 7-week overfeeding period, and 
response to LNA administration was examined in the lean and obese state.
Body weight increased from 19.9 ± 0.70 to 29.7 ± 0.77kg and % body 
fat from 23.0% to 48.8% during overfeeding (OF). Heart rate, MAP and 
plasma insulin also increased during overfeeding. Femoral vascular 
resistance initially increased (p<0.01 in both the intact and denervated 
limbs), but returned to baseline levels by OF-week 3 in the denervated limb, 
and by week 6 in the intact limb. No significant correlation was evident 
between insulin levels and other cardiovascular parameters.
Hyperinsulinémie euglycemia alone did not affect MAP in  either 
weight group. However, when hyperinsulinemia was initiated following 
NOS inhibition, MAP in the lean animals tended to decrease, whereas th a t 
of the obese dogs increased slightly. HR response to hyperinsulinemia 
(alone or concurrent with NOS inhibition) was not different between weight 
groups. The FVR response to hyperinsulinemia alone or w ith NOS
ix
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inhibition was not different between the weight groups. However, heart 
rate and vascular response to LNA was reduced in the obese dog.
In summary, sympathetic activity may influence the vascular 
response to weight gain. Also, hyperinsulinemia does not affect MAP, HR or 
FVR in lean or obese dogs, while walking slowly on a treadmill. However, 
when NOS is concurrently inhibited, lean and obese dogs show a tendency 
toward differential MAP and HR responses to hyperinsulinemia. Thus, the 
insulin and nitric oxide interaction may differ in lean and obese dogs, and 
may mediate development of hypertension in the obese population. Finally, 
the obese have a reduced cardiovascular response to NOS inhibition 
compared to the lean.
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CHAPTER 1: IN TR O D U C TIO N
Obesity-induced hypertension is a  significant clinical health risk. 
Approximately 25% - 50% of hypertensive people are obese (Hseuh and 
Buchanan, 1994), with the majority dem onstrating significant reduction in 
blood pressure following weight loss (e.g., Weinsier et al., 1991). However, 
the exact mechanism by which obesity-induced hypertension develops has 
not been fully elucidated. In recent years, studies exam ining the 
mechanisms through which hypertension develops with obesity have 
concentrated on the role of hyperinsulinemia and insulin resistance (For 
reviews see Modan and Halkin, 1991; H all et al., 1994; Landsberg, 1991). 
Both obese and non-obese hypertensive individuals are insulin resistant 
(Ferrannini et al., 1987), with significant correlation observed between 
circulating insulin levels and blood pressure. Despite these data, more 
recent studies report tha t hyperinsulinemia alone does not elevate blood 
pressure in either normal or insulin resistant dogs (Brands et al., 1991; Hall 
et al., 1990 & 1995). However, hyperinsulinemia does elevate arterial 
pressure in the ra t (Meehan et al., 1994), and activation of the sympathetic 
nervous system (SNS) may be one mechanism through which insulin may 
promote elevations in arterial pressure (Daly and Landsberg, 1991). Thus, 
controversy remains as to the involvement of insulin/insulin resistance in 
obesity-induced hypertension.
There is a growing body of evidence th a t the obese state results in an 
altered pattern of sympathetic activity. Increased norepinephrine levels
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
have been observed in overweight hypertensive individuals (Rocchini e t al.,
1989), which could potentially mediate elevations in arterial pressure 
through increases in peripheral resistance and/or altered renal function 
precipitating fluid and sodium retention (DiBona, 1992). Acute elevations 
in  insulin stimulate sympathetic activity in several species (Young et al. 
1988; Liang et al., 1982; Rowe et al., 1981), and may be one mechanism 
through which elevations in arterial pressure occur (Daly and Landsberg,
1991). Still, others have shown vasodilation in skeletal muscle by insulin 
(for review see Baron, 1994). However, in insulin resistant subjects (e.g. 
obese), this response is reduced (Laakso et al., 1990). In addition, the 
response to vasoconstricting agents is enhanced in insulin resistant rats 
(Townsend et al., 1992). Thus, the obese insulin resistant state could 
predispose to changes in vascular resistance consistent with elevations in 
arterial pressure through alterations in SNS activity. Recent evidence 
suggests that altered sympathetic activity is essential for the development 
of obesity-related hypertension, via renal mechanisms (Kassab et al., 1994). 
However, the exact role sympathetic activity plays in the development and 
maintenance of obesity-induced hypertension remains obscure.
Another factor which may play a crucial role in the etiology of 
obesity-associated hypertension is nitric oxide. Nitric oxide (NO) has come 
under much scrutiny for its abihty to cause vascular relaxation and 
reductions in peripheral resistance. It is also a potential modulator of 
nervous, renal and immune system function. Initial studies suggest that
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the nitric oxide system may be important in various organ systems for 
normal physiologic functioning as well as in some disease states.
Since acute and chronic NO inhibition results in increased arterial 
pressure in several species, the role of NO as a possible mediator of 
cardiovascular hemodynamics and vascular responses in various models of 
hypertension has received much examination (Panza et al., 1993; Lockette 
et al., 1986; Roller et al., 1994). In 1990, Panza et al. described abnormal 
vascular relaxation in patients with essential hypertension, which was later 
found to be, a t least in part, due to a defect in the NO system (Panza et al., 
1993a, b). A potential role for the nitric oxide system in nervous tissue 
function has been explored. Studies suggest that in addition to modulating 
vascular resistance through peripheral mechanisms, NO may play a role in 
central regulation of sympathetic tone and/or renal nerve activity, while 
other experiments suggest th a t sympathetic activation is a modulator of NO 
release (LacoUey et al., 1991).
In addition to interactions with the nervous system, nitric oxide 
activity has also been studied with regard to its actions on in sulin release, 
activity and sensitivity. Recent studies report that the vasodilating effects 
of insulin are mediated through the stimulation or synthesis/release of 
nitric oxide. (Scherrer et al., 1994, Steinberg et al., 1994). There is a 
suggestion in the literature tha t a positive relationship exists between 
endothelial nitric oxide production and insulin sensitivity (Petrie et 
al., 1996). This finding is supported in the study by Higashi, e t al. 1997, in
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which the increase in renal plasma flow, the decrease in renal vascular 
resistance and filtration firaction and the increase in cGMP in response to 
arginine infusion was reduced in essential hypertensive subjects. Also, 
these insulin resistant individuals showed a higher insulin response to L- 
arginine infusion compared to their normotensive, insulin sensitive 
counterparts. Thus, a  relationship exists between insulin, insulin 
sensitivity and endothehal nitric oxide, and defects in  any aspect of this 
system could be a potential mediator of hypertension observed in  insulin 
resistant states such as obesity. However, these interactions have yet to be 
described in the obese.
Thus, our objectives were to examine the interaction between insulin, 
the SNS and nitric oxide in mediating femoral blood flow and vascular 
resistance in conscious lean and obese dogs. Also, since httle information on 
the time course of vascular resistance changes and the onset of insulin 
resistance occurring w ith obesity is currently available in the literature, we 
followed these param eters over seven weeks of overfeeding and weight gain.
To study the interaction of insulin and sympathetic activity in 
mediating vascular resistance in the lean state and w ith the development of 
obesity, the hyperinsulinémie euglycemic clamp (HIEC) technique was 
utilized in  lean and obese dogs with unilateral lum bar sympathetic 
denervation. To determine whether the nitric oxide system is also involved 
in the development of obesity-related hypertension through either 
interactions with the SNS and/or insulin, we examined the effects of nitric
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
oxide synthase inhibition on the cardiovascular responses during the HIEC 
in the same lean and obese dogs. Last, we examined whether changes in 
vascular resistance and hyperinsulinemia develop concurrently during the 
course of the development of diet-induced obesity, and whether the vascular 
changes were affected by sympathetic innervation. To procure these data, 
weekly standing and walking femoral blood flow and fasting insulin and 
glucose levels were monitored over the course of development of obesity in 
lumbar sympathectomized dogs. Thus, the time course for development of 
vascular resistance changes, hyperinsulinemia, and correlation between the 
two param eters could be determined.
We hypothesize tha t as insulin resistance develops w ith weight gain, 
insulin’s effect to reduce vascular resistance is decreased. A t this time, 
increases in SNS activity associated with obesity alter peripheral vascular 
resistance, laying a foundation for hypertension to develop. We also 
hypothesize that the increase in SNS activity which develops with weight 
gain inhibit the activity of vascular nitric oxide synthase (NOS), thereby 
predisposing to hypertension in the obese. Additionally, this reduction in 
nitric oxide activity may influence cardiovascular responses to insulin and 
influence arterial pressure, since there is suggestion in the h terature that 
nitric oxide may mediate the vascular effects of insulin (Steinberg et al., 
1994, Scherrer et al., 1994).
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CHAPTER 2: REVIEW  OF LITERATURE
Along with atherosclerotic vascular disease and certain cancers, the 
risk of hypertension is increased with obesity (Kannel et al., 1967). In 
addition, obesity is reported as an  independent predictor of stroke, 
cardiovascular death, coronary artery disease and congestive heart failure 
(Hubert et al., 1983). Hypertension itself is a major risk factor for coronary 
heart disease, stroke and congestive heart failure (Kannel et al., 1972 and 
1976; Pooling Project, 1978). Thus, obesity-induced hypertension is a 
significant clinical health risk afOicting humans.
Approximately 25% - 50% of obese individuals are hypertensive 
(Hseuh and Buchanan, 1994), with the majority demonstrating significant 
reduction in blood pressure following weight loss (for example, Weinsier et 
al., 1991). Although the exact mechanisms by which hypertension develops 
in the obese remain obscure, increases in cardiac output and blood volume, 
insulin resistance and renal sodium retention are reported to occur 
concurrent with weight gain and the development of hypertension in both 
humans and the canine model (Alexander et al., 1962; Mujais et al., 1982; 
Rocchini et al., 1987 and 1989a, b, c). Also, the acute response to sodium 
loading, the pressor response to angiotensin H, and catecholamine levels are 
altered in obese hypertensive hum an patients and in a n im al models 
(Rocchini et al., 1989a, b, c and 1990; West et al., 1991; Rowe et al., 1981; 
Tuck et al., 1992).
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For many years, studies examining the mechanisms of obesity related 
hypertension concentrated on the role of hyperinsulinemia and insulin 
resistance (For review see Modan et al., 1991; Hall et al., 1994; Landsberg, 
1986). Both obese and non-obese hypertensives are insulin resistant 
(Ferrannini et al., 1987), with significant correlation between circulating 
insulin levels and blood pressure. In addition, strong correlation has been 
identified between hypertension and insulin resistance in several disorders 
(non-insulin dependent diabetes meUitus [NIDDM], obesity), and insulin 
infusion in rats elevates arterial pressure (Qadir et al., 1996). Thus, 
hyperinsulinemia and insulin resistance were hypothesized to be primary 
factors in the development of hypertension in the obese, through either 
direct effects on renal Na+ absorption or via insulin-induced activation of 
the sympathetic nervous system (SNS) w ith resultant changes in vascular 
resistance and/or renal sodium handling. However, a growing body of 
evidence suggests tha t the obese state results in an altered pattern  of 
sympathetic activity to peripheral resistance vessels and the kidneys, which 
is essential for the development of obesity-related hypertension (Kassab et 
al., 1994). Still, the specific mechanisms through which hypertension 
develops with weight gain rem ain obscure, and investigators now are 
considering the involvement of the nitric oxide system as an  additional piece 
to the insulin and hypertension puzzle.
Over the time course of research into the cause of obesity-induced 
hypertension, the hyperinsulinemia and insulin resistance associated with
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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this disorder has received a vast amount of interest. This in terest was 
sparked by observations th a t insulin resistance and glucose intolerance 
were correlated w ith the development of hypertension in both obese and 
non-obese subjects (Bonora et al., 1987; Lucas et al., 1985; Modan et al., 
1985; Ferannini et al., 1987; Manicardi et al., 1986; Rocchini e t al, 1987 and 
1989a). In 1986, Lewis Landsberg published a schematic of direct and 
indirect mechanisms through which hyperinsuhnemia/insulin resistance 
could potentially result in hypertension with obesity (Figure 1).
In short, with weight gain, insulin levels increase during the 
development of insulin resistance (primarily skeletal muscle insulin 
resistance). As this occurs, elevated insulin stimulates the SNS resulting in 
increases in peripheral and/or renal vascular resistance and h eart rate, 
predisposing to hypertension. Along with these changes, the increase in 
insulin could directly alter renal sodium handling, thereby altering whole 
body fluid balance and potentiating increases in blood pressure. Thus, in 
this model, there are several mechanisms warranting experimentation to 
decipher the pathway(s) responsible for the elevation in arterial pressure 
associated with weight gain. However, all revolve around 
hyperinsulinemia/insulin resistance as the primary/inciting factor.
Contradictory to this hypothesis, insulin has been shown to produce 
vasodilatation in skeletal muscle vasculature, with associated increases in 
blood flow (For review see Baron, 1994). This, intuitively, should tend  to 
reduce MAP. However, in obesity this response is impaired (Laakso et al..
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Figure 1: Summary of mechanisms possibly resulting in obesity-related 
hypertension. Copied with sbght modification from Landsberg, 1986.
1990). In  1993, Feldman and Bierbrier reported decreasing vascular 
sensitivity to insulin with increasing body mass in men. Also, the potency 
of in s u lin  as a venodilator was reduced 79% in the mildly hypertensive 
subjects of this study. In addition to the above f in d in gs, the vascular 
response to vasoconstrictive agents has been shown to be enhanced in 
insulin resistant rats (Townsend et al., 1992). Thus, although in s u lin  has 
been shown to increase blood flow and reduce vascular resistance, changes
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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in tissue response to insulin in obesity, in conjunction with, altered 
sympathetic activity, could mediate the development of obesity-induced 
hypertension. In addition, the influence of insulin and the SNS in the 
control of peripheral vascular resistance or renal function may vary over the 
time course of the development of obesity-induced hypertension (Kraegen et 
al., 1991; Penicaud et al., 1987). Insulin sensitivity of the kidneys and 
skeletal muscle changes during the development of obesity. Thus, as 
insulin resistance develops in the vasculature and kidneys, sympathetic 
activity may become the primary factor mediating increased peripheral 
vascular resistance and/or renal sodium retention during the 
development/maintenance of obesity.
In studies to further describe mechanisms through which insulin may 
influence arterial pressure, the sodium r e t a in in g  effects of in s u lin  have been 
clearly demonstrated in vitro using isolated dog kidneys (Baum et al., 1987; 
Nizet et al., 1971) and renal micropuncture techniques (DeFronzo et al., 
1976). These studies suggest that in s u lin  has direct effects in vitro to 
promote sodium reabsorption across the thick loop of the ascending limb of 
Henle and the proximal and distal renal tubules. In vivo, these effects could 
predispose to the development of hypertension in the obese, as obesity is an 
insulin resistant/hyperinsulinemic and volume-expanded state, with 
increased cardiac output and sodium retention (Rocchini e t al., 1987 and 
1989a, b, c). Although these vascular and renal effects of in s u lin  may be
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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important factors involved in the development of hypertension in  the obese, 
Hall and colleagues (1990, 1991 and 1995; Brands et al., 1991) have shown 
that hyperinsulinemia alone does not result in elevated blood pressure in 
the dog. Thus, the development of in s u lin  resistance and interactions with 
other systems such as the SNS or nitric oxide are likely to be im portant 
factors which mediate the development of obesity-induced hypertension.
The development of insulin resistance in different tissues such as the 
kidney, liver and skeletal muscle is thought to occur at different rates 
(Kraegen et al., 1991; Penicaud et al., 1987). Hence, the physiologic 
responses of these tissues, and their relationship to circulatory/arterial 
pressure control, may vary over the course of the development of 
hypertension in the obese.
Recent evidence in the obesity-induced hypertensive dog model 
suggests tha t renal innervation is a primary mechanism required for the 
development of hypertension (Kassab et al., 1994). In this study, renal 
denervation attenuated the development of increased arterial pressure with 
the development of obesity. Another study by this same group (Kassab et 
al., 1995) suggests th a t the renal sympathetic activity may be im portant 
during the development of obesity-induced hypertension, since basal urine 
sodium excretion of innervated kidneys of obese dogs was significantly  
lower than  that of the lean control animals. This difference was abolished 
using bilateral renal denervation in the obese dogs, but denervation had no 
effect on basal urinary sodium excretion in the lean controls. These data
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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support the idea tha t renal sympathetic activity m ay be activated and 
responsible, in part, for the development of obesity-associated hypertension. 
However, increases in sympathetic activity could also predispose to 
increased arterial pressure in the obese patient through alterations in 
peripheral vascular resistance (DiBona, 1992). Insulin has been shown to 
have multiple effects on the sympathetic and cardiovascular systems th a t 
could potentially result in hypertension. Thus, the interaction of insulin 
and these systems should be considered in the etiology of obesity-related 
hypertension.
For years the sympathetic nervous system has been suggested as a 
possible mechanism for hypertension. Increased SNS activity is reported to 
occur in obesity-related hypertension, as increased circulating 
norepinephrine levels have been observed (Rocchini e t al., 1989a, b, c). 
Increased SNS activity may mediate elevations in arte ria l pressure in  the 
obese through either increases in peripheral vascular resistance or renal 
mechanisms (DiBona, 1992). Changes in sympathetic activity may be an 
integral mechanism through which hypertension develops with obesity, 
since Kassab et al. (1994) provided evidence th a t renal innervation is 
crucial for the development of hypertension in diet-induced obesity in the 
canine model. Investigation into the interaction of insulin  and sympathetic 
activity as a mechanism for hypertension has been fueled by the finding 
th a t insulin infusion causes increased heart rate and cardiac output, and 
elevations in circulating norepinephrine (Viberti et al., 1981; Rowe et al..
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1981). Studies such as these lay groundwork for the thought th a t 
hyperinsulineinia in insulin resistant obese patients may stim ulate SNS 
activity, which may then increase vascular resistance or reduce renal 
sodium and w ater excretion, predisposing to hypertension (Figure 1). 
Numerous studies using the hyperinsulinémie euglycemic clamp in rats 
(Young, 1988), dogs (Liang et al., 1982) and humans (Rowe et al., 1981) 
demonstrate th a t acute elevations of insulin will stimulate sympathetic 
activity. Assessment of circulating norepinephrine levels, changes in 
regional blood flow, or direct nerve recordings were examined as measures 
of SNS activity. In a recent study using microelectrode nerve recordings 
during euglycemic hyperinsulinemia, muscle sympathetic nerve activity 
increased significantly during insulin infusion a t both normal and supra- 
physiologic insulin levels (Berne, et al., 1992). In this study, 
hyperinsulinemia was associated with increased vasoconstrictor nerve 
activity to skeletal muscle, but blood pressure was not notably affected. 
This suggests a  direct stimulatory effect of hyperinsulinemia on vascular 
sympathetic activity, without a significant associated arterial pressure 
increase. Another recent study demonstrated th a t sympathetic nerve 
hyperactivity precedes the appearance of hyperinsulinemia and MAP 
elevations in a  non-obese population (Masuo, 1997). Thus, the mechanisms 
through which hypertension is mediated, and how they are altered in 
insulin resistant and/or hypertensive states such as obesity, may be closely 
related to sympathetic activity. The importance of SNS activity in
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hypertension is gaining more support, as a  recent study in humans 
(Facchini, 1996) reported tha t increased heart rate and insulin resistance 
are highly correlated in humans, and this increase in heart rate 
presum ably reflecting increased cardiac output) is consistent with insuhn- 
induced increases in sympathetic activity. However, other studies have 
previously reported that the increase in heart rate observed with obesity is 
the result of a reduction in parasympathetic nervous system activity 
controlling heart rate (Truett et al., 1996; Kirsch et al., 1991). Using 
microneurography, Anderson et al. (1991 and 1992), reported tha t 
physiologic increases in plasma insulin elevate sympathetic outflow in 
healthy and borderline hypertensives, but produce vasodilation and do not 
elevate blood pressure. Lembo et al., (1992) reported similar basal glucose 
uptake in normal and hypertensive subjects, with considerable increases in 
glucose uptake in response to insulin. However, the glucose uptake levels 
attained in the hypertensive group were significantly lower than those of 
the controls. During the hyperinsulinémie period of these studies, forearm 
norepinephrine (NE) release increased by 35% in normotensive patients. 
This was considerably greater in the hypertensive group, who exhibited a 
140% increase in NE release. Nevertheless, the mechanism by which 
insulin induces muscle sympathetic overactivity is not yet completely 
understood. Suggested hypotheses include action on the central nervous 
system (CNS: ventromedial hypothalamic neurons), an indirect baroreflex- 
mediated action and a direct effect on muscle (for review, see Lembo e t al..
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1996). The majority of data suggests that the effect of insulin on muscle NE 
is mediated through either central mechanisms or peripheral reflexes 
(Lembo et al, 1996 for review). However, one m ust consider tha t the clamp 
procedure itself, with only saline infusion, is reported to increase 
norepinephrine levels without elevating blood pressure (Moan et al., 1995). 
This questions whether changes in SNS activity described in previous clamp 
studies were a result of the experimental procedure, or insulin, per se. This 
requires further study. Regardless, the studies mentioned suggest tha t 
alterations in autonomic/sympathetic activity which occur in  obesity may be 
a more important mediator of hypertension in the obese than  originally 
implied, and the mechanism may involve interaction with insulin. Also, 
these pathways may involve interaction with other vasoactive factors such 
as nitric oxide, as one study reports that insulin-induced vasodilatory 
responses are not mediated by beta-adrenergic or cholinergic mechanisms, 
and are not markedly affected by alpha-adrenergic mediated mechanisms 
(Randin et al., 1994).
Although much study has examined the influence of insulin on 
sympathetic activity, the sympathetic nervous system has also been 
explored as a possible modulator of insulin-induced glucose uptake. This 
question is much more difficxdt to explore, since norepinephrine (NE) is a 
neurotransmitter, and circulating levels only poorly reflect synaptic cleft 
concentrations (Lembo, 1992). The idea th a t NE may potentially alter 
insulin action is suggested by the observation th a t in various models of
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complete sympathectomy, the normalization of glucose &om insulin-induced 
hypoglycemia is impaired (Sacca et al., 1977; Schacter et al., 1951; 
McDonough, 1939). This does not occur with reduced epinephrine levels, 
suggesting a metabolic role for NE (Gerich et al., 1979). In 1994, Lembo 
and colleagues directly tested whether NE release was able to provoke an 
impairment in in su lin  sensitivity measured using the in s u lin  euglycemic 
clamp technique. They observed th a t when insulin was infused during 
lower body negative pressure (LBNP; a technique used to stim ulate 
baroreflex activation of NE release by applying negative pressure to the 
body below the iliac crest using a pressurized airtight chamber) the 
increment in forearm NE release was greater than  in control LBNP studies 
(Lembo et al., 1994a). Also, forearm glucose uptake was activated during 
in s u lin  infusion in control and LBNP patients, but the values obtained 
during LBNP were 40% lower than  during the control study. Additional 
data supporting these observations has been presented by others (Jamerson 
et al., 1993 and 1994). Possible mechanisms by which LBNP im pairs 
in s u lin  action on muscle glucose uptake are either via hemodynamic 
mechanisms leading to reduced perfusion or through direct metaboHc effects 
of NE a t the cellular level (For review see Lembo, 1996). The first 
mechanism is supported by a report th a t there is a reduced effect of insulin 
to stimulate skeletal muscle blood flow in obese men (Laakso e t al., 1990). 
However, Capaldo et al., 1991 found th a t although skeletal muscle is a 
major site of insulin resistance in essential hypertension, the defect is
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independent of muscle blood flow. In a  separate study, impaired insulin- 
mediated augmentation of blood flow in obese NIDDM patients was 
attributed to the diabetic state rather than  the obese status (Laakso e t al.,
1992). Other studies, however, also suggest increased sympathetic drive as 
a primary influence in hypertension (Egan, 1989; JuHus, 1988; Reis, 1988). 
Thus, sympathetic activity may influence insulin-mediated vascular 
responses as well as contribute as a primary factor to precipitate 
hypertension in the obese.
Insulin modulation of sympathetic-mediated vasoconstriction is 
another avenue through which these systems may predispose to 
hypertension, and has incited much interest and scrutiny. In two separate 
studies, a marked increase in sympathetic activity (measured by 
norepinephrine levels and/or muscle sympathetic nerve activity) evoked by 
insulin did not produce changes in arterial pressure or forearm vascular 
resistance in humans (Anderson et al., 1991; Lembo et al., 1992). These 
observations support the hypothesis tha t insulin per se is able to blunt 
sympathetic-induced vasoconstriction. In one study, fat-fed dogs exhibited a 
loss of coronary artery vasodilation to local hyperinsulinemia (Rocchini et 
al., 1996). This is consistent with previous work showing reduced glucose 
uptake in essential hypertensive individuals (Natali et al, 1991), and the 
observation tha t this reduction may be due in large part to an impairment 
in the action of insulin to increase skeletal muscle blood flow in obesity and
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hypertension (Baron et al., 1988; Laakso et al., 1992; Baron et al., 1991). 
Investigations using LBNP and insulin infusion found th a t increases in 
forearm vascular resistance normally observed with LBNP are blunted 
during insulin infusion (Lembo et al., 1993). Biochemical studies have 
demonstrated that insulin interferes with the az-adrenergic receptor- 
mediated vascular effects (Devedgian et al., 1991), while additional findings 
seem to suggest that it selectively interferes with transduction of the az- 
vasoconstrictor signal (Lembo et al., 1994b ). A growing body of evidence 
proposes th a t insulin's hemodynamic effects may be mediated by enhanced 
endothelial function (Steinberg et al., 1994; Scherrer et al., 1994). Thus it is 
reasonable to propose th a t changes in the interaction of insulin, endothehal 
derived vasoactive factors (such as nitric oxide) and the SNS may modulate 
vascular effects, thereby influencing the development of hypertension with 
weight gain.
Nitric oxide (NO) is one vasoactive factor which may play a crucial 
role in the complex relationships influencing vascular changes predisposing 
to obesity-associated hypertension. In recent years, nitric oxide has come 
under much scrutiny for its abihty to induce vascular relaxation and 
reductions in  peripheral resistance, and as a potential modulator of nervous, 
renal and immune system function. Initial studies suggest th a t the nitric 
oxide system may be important in various organ systems for normal
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physiologie functioning, as well as having an instrum ental role in various 
disease states.
Nitric oxide has been identified as the major functional component of, 
or is identical to, the local vasodilator endothehal-derived relaxing factor 
(Palmer et al., 1987; Ingarro et al., 1987). I t is a nitroso compound derived 
from the local oxidation of L-arginine (Palmer et al., 1988a, b; Sakuma et 
al., 1988) by the enzymatic actions of nitric oxide synthase. Nitric oxide 
synthase has been located in various body tissues in several isoforms which 
have been purified and characterized (Forstermann et al., 1991). Nitric 
oxide is reported to exist as either a constitutive or inducible enzyme in 
many cells and tissues, including vascular endothehal cells, macrophages, 
hepatocytes, the cerebellum and cerebrum, the pituitary gland, the nucleus 
tractus sohtarius and the kidneys, to name a few (Forstermann et al., 1991; 
Moncada et al., 1991; Bredt et al., 1990). AU isoforms require oxygen, 
NADPH and 5,6,7,8-tetrahydrobiopterin as cofactors, w ith some variation 
existing between isoforms as to other factor requirements and the nature of 
the isoform as either a particulate or soluble type of enzyme (Forstermann 
et al., 1991).
Competitive inhibition of NO synthesis has been achieved using L-
arginine derivatives such as L-N°-monomethyl arginine (Palmer et al.,
1988b; Sakuma et al., 1988). The potency of inhibition obtained using L- 
arginine derivatives can vary, depending upon the tissue studied and the
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drug used. N -nitro-L-arginine was found to be more potent than  N - 
methyl-L-arginine in inhibiting NO synthesis in  the brain and endothelial 
cells, but less potent in induced macrophages (Lambert et al., 1991; Gross et 
al., 1990). Differences in potency between inhibitors were also
demonstrated in a study by O kum ura et al., 1992, in which N^-nitro-L- 
arginine (LNNA) was more potent in ehciting renal vasoconstriction th an
was L-N^-monomethyl-arginine (LNMMA).
Endothelial NO acts via the stimulation of soluble guanylate cyclase 
to increase intracellular guanosine 3’, 5’-cyclic monophosphate (cGMP), 
thereby inducing smooth muscle relaxation (for review see Bassenge and 
Heusch, 1990; Moncada et al., 1991). Basal/continuous release of NO occurs 
in the vascular endothehum, bu t a stimulated release may be initiated by 
several vasoactive substances such as acetylcholine or bradykinin, or by 
mechanical stimuli such as pulsatile flow or shear stress (Bassenge/Heusch, 
1990; Moncada et al., 1991; Rubanyi et al., 1986; Rees et al., 1989). These 
characteristics of NO make it ideally suited for a  role in acute and/or 
chronic modulation of blood pressure and vascular resistance.
The vasorelaxing properties of NO have been directly demonstrated 
in several in vitro preparations (Moncada et al., 1991; Komori et al., 1988). 
Recent in vivo studies have shown th a t NO synthesis inhibition using L- 
arginine derivatives results in elevations of arterial pressure in dogs 
(Manning et al., 1993 and 1994; Eisner et al., 1992), rats (Perrella et al..
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1991; Ribiero et al., 1992) and rabbits (Rees e t al., 1989). With NOS 
inhibition total peripheral resistance increases as does renal vascular 
resistance, with decreased renal plasma flow, urine flow and sodium 
excretion, but little change in glomerular filtration rate (Eisner et al., 1992; 
Baumann et al., 1992; Majid and Navar, 1992). However, in studies by 
Salazar et al. (1992 and 1993), low doses of the nitric oxide synthase 
inhibitor N^-nitro-L-arginine-methyl ester (L-NAME) infused in dogs for 3 
or 5 days caused renal vasoconstriction, but did not result in hypertension 
unless sodium intake was increased (Salazar et al., 1993). The results of a 
study by Granger and colleagues (1992) comparing intrarenal versus 
systemic effects of NO blockade indicate tha t the renal effects of L-NAME 
are largely secondary to extrarenal effects of NO inhibition, and 
speculations were made as to a possible role of SNS activation. Thus, since 
reduced sodium excretion and increased extracellular fluid volume have 
been reported to occur with obesity-induced hypertension in dogs, and 
increased catecholamine levels have also been suggested to occur with 
obesity (Tuck et al., 1992; Rocchini et al., 1989b), the function of the nitric 
oxide system deserves study as a possible mediator of these changes during 
the development or maintenance of hypertension in the obese.
The role of NO as a mediator of cardiovascular hemodynamics and 
vascular responses in various models of hypertension has received much 
examination, as acute and chronic NO inhibition results in increased 
arterial pressure in several species, (Lockette et al., 1986; Panza et al..
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1993a, b; KoUer and Huang, 1994). Using three models of hypertension in 
the rat, Lockette et al. (1986) showed a loss of endothelium-dependent 
relaxation during development of hypertension, which they felt was related 
to the elevated blood pressure. In 1990, Panza et al. described abnormal 
vascular relaxation in patients with essential hypertension, whose forearm 
response of blood flow and vascular resistance to acetylcholine (ACH), but 
not sodium nitroprusside, were significantly lower than  controls. This 
impaired response to endothehal-derived vasodilators and the increased 
basal vascular resistance in essential hypertension was later found to be 
due, at least in part, to a defect in the NO system (Panza et al., 1993a, b), 
but not related to decreased availabüity of substrate for NO synthesis 
(Panza et al., 1993b). Diabetic subjects (NIDDM) are reported to have 
attenuation of blood flow, which is reportedly due to either increased 
inactivation of nitric oxide or decreased reactivity of the vascular smooth 
muscle to NO (Wilhams et al., 1996). In the spontaneously hypertensive rat 
(SHE), reductions in arteriolar dilation in response to increases in flow are 
attributed to impairment of the nitric oxide-mediated portion of flow- 
dependent arteriolar dilation (Koller and Huang, 1994). Thus, data  are 
accumulating which link the function of the nitric oxide system to the 
development of hypertension, although data are lacking which link altered 
function of the nitric oxide system to obesity-associated hypertension.
In addition to the reports of abnormal responses to nitric oxide 
blockade, essential hypertensive patients have decreased endothelial nitric
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oxide synthesis (Calver et al., 1992). Also, a positive relationship has been 
reported between insulin sensitivity and endothehal nitric oxide synthesis 
by Petrie et al., 1996 in a study examining forearm vasoconstrictor 
responses to hyperinsulinémie euglycemia and NOS inhibition. Thus, 
another mechanism through which NO may be associated with obesity- 
induced hypertension is through interaction with insulin. In a study by 
Walker, et al. (1997) insulin attenuated the contractile response to 
noradrenaline in rat mesenteric arteries. This effect was blunted by L- 
NAME, supporting the idea that insulin's effect to reduce the 
vasoconstriction induced by noradrenaline is nitric oxide dependent. This 
group proposed several mechanisms through which L-NAME could work to 
oppose the abihty of insulin to blunt norepinephrine-induced 
vasoconstriction:
1) inhibiting NO synthase - probable
2) altering insulin binding
3) interfering with insulin metabohsm
It is possible to postulate tha t insulin-induced release of NO occurs at 
physiologic insulin levels, resulting in tonic vasodilation. Insulin resistance 
is known to occur in essential hypertension (Ferrannini et al., 1987). Thus, 
developing insulin resistance may be associated w ith impaired insulin- 
induced NO release and a loss of this tonic vasodilating stimulus, with 
subsequent development of hypertension (Baron, 1996).
An alternate interaction between NO and in sulin is suggested by 
recent studies in dogs (Büski et al., 1995a and b) which report th a t NO may
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be an  important neurotransm itter in the pancreas. In these studies, L- 
arginine infusion resulted in a significant increase in pancreatic protein 
output (a reflection of exocrine pancreatic function), and LNNA caused 
significant reductions in insulin and glucose. Their paradigm of LNNA use 
alm ost abolished the increment of insulin and glucagon in response to sham 
and ordinary feeding. However, this LNNA infusion did not change basal 
pancreatic protein secretion. They proposed th a t these effects were 
probably mediated through cholinergic mechanisms, since direct cholinergic 
stim ulation of insulin secretion was blocked w ith the LNNA treatm ent. 
O ther studies support the role of NO in both exocrine and endocrine 
pancreatic secretion in humans (Konturek et al., 1997). In this study, 
secretin and caerulin-stimulated pancreatic enzyme secretion was reduced 
by LNMMA, without alterations in volume flow and bicarbonate outputs. 
Addition of LNMMA to the secretagogue infusion was associated w ith a 
reduction in plasma insulin and pancreatic polypeptide (PP) levels, while 
addition of L-arginine raised insulin and PP levels above normal. This 
supports a role for NO in pancreatic insulin secretion, another avenue 
through which these two factors may interact. Thus, there are several 
pathways through which the nitric oxide system and insulin may interact to 
influence arterial pressure in hypertensive disorders. These require 
examination in the obese model of hypertension as mediators of this disease 
syndrome.
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In addition to its involvement in cardiovascular hemodynamic 
function, the role of the nitric oxide system in nervous tissue function has 
been explored. Nitric oxide synthase activity has been identified in several 
CNS locations (Bredt et al., 1990; Forstermann et al., 1991), and studies 
exploring a regulatory role for NO in functioning of the sympathetic nervous 
system have been performed (Harada et al., 1993; Sakuma et al., 1992). In 
1991, Vo et al. demonstrated that central inhibition of NO synthesis 
enhances the vasoconstrictor responses to peripheral sympathetic nerve 
stimulation and adrenaline in the ra t tail artery. In 1993, Harada, et al. 
examined the effects of microinjections of L-arginine into the nucleus 
tractus sohtarius (NTS) on blood pressure, heart rate and renal nerve 
activity. The results of this study suggests that NO is involved in NTS 
mechanisms that mediate tonic renal nerve activity in rabbits, providing 
support for central NO synthase activity in the regulation of renal 
sympathetic nerve activity. Intravenous LNMMA administration in 
sinoaortic-denervated and vagotomized rats increased renal sympathetic 
nerve activity (Sakuma et al., 1992), while Togashi and his colleagues, 
ehcited elevations in arterial pressure and renal sympathetic nerve activity 
with intra-cisternal injections of LNMMA (Togashi et al., 1992). These 
studies further support central regulation of peripheral SNS activity by NO. 
Thus, in addition to modulating vascular resistance by peripheral 
mechanisms, NO may play a role in central regulation of sympathetic tone 
and/or renal nerve activity.
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Other experiments have suggested tha t sympathetic activation is in 
tu rn  a modulator of NO release (LacoUey et al., 1991). In 1991, LacoUey 
suggested that the SNS plays an important role in modulating the synthesis 
or release of vascular NO through the effects of normal sympathetic 
discharge, humoral activation of a-adrenergic receptors and vascular tone 
per se, since ganghonic blockade with chlorisondamine lowered mean 
arterial pressure and vascular resistance, abolished the LNA-induced 
pressor and renal vasoconstrictor responses, and attenuated the increase in 
mesenteric and hindquarter resistance in rats. In 1992, Pegoraro et al. 
suggested that NO synthesis may be stimulated by alpha-1 receptors due to 
a  greater response to NO synthesis inhibition in phenylephrine-pretreated 
rats.
Thus, the role of NO synthase activity in central and peripheral 
regulation of vascular, renal and nervous system control is complex. There 
is clear evidence that central NO production can modulate sympathetic 
nervous system activity as well as evidence that peripheral sympathetic 
activity can modulate both the production and the action of NO in 
peripheral vessels. Although it is clear tha t these two systems interact, it is 
not clear how, or if, they interact in the pathogenesis of hypertension in 
either the lean or the obese state. The involvement of these two systems 
with insulin and insulin resistant disease states further compHcates the 
mechanisms through which hypertension could develop with obesity.
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Further study of this triad as modulators of obesity-hypertension is thus 
warranted.
The studies described in this dissertation were designed to examine 
the interactions of insulin, the SNS and nitric oxide in lean and obese- 
hypertensive dogs, further characterizing the mechanisms responsible for 
the development of hypertension with obesity. This was accomplished using 
the canine model of obesity-induced hypertension, the hyperinsulinémie 
euglycemic clamp technique, nitric oxide synthase inhibition and unilateral 
lumbar ganghonectomy to examine the following hypotheses.
1) The interaction of hyperinsulinemia and sympathetic activity were 
examined over the course of weight gain to determine whether changing 
vascular resistance is influenced by insulin or SNS activity, predisposing to 
arterial pressure increases. We hypothesize th a t as insulin resistance 
develops w ith weight gain, insulin’s effect to reduce vascular resistance is 
decreased. At this time, increases in SNS activity associated with obesity 
alter peripheral vascular resistance, laying a foundation for hypertension to 
develop. Thus, in animals with nervous activity removed to one limb (while 
the SNS of the opposite limb remains intact), we monitored insulin levels 
and femoral vascular resistance (FVR) throughout weight gain to determine 
whether the vascular response to weight gain correlated with insulin levels, 
and were influenced by SNS innervation.
2) Local NOS activity reduces peripheral vascular resistance, but this 
function may be reduced in the obese. Peripheral sympathetic activity may
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be im portant in modulating vascular responses to nitric oxide, and  this 
interaction may be altered in the obese animal. We hypothesize th a t the 
increase in SNS activity which develops with weight gain may inhibit the 
activity of vascular NOS, thereby predisposing to hypertension. Thus, the 
vascular response to nitric oxide synthase inhibition in intact and  
denervated femoral arteries in the lean animals should vary slightly, due to 
differences in basal tone resultant from nerve input. However, as 
sympathetic activity increases in obesity, there should be a reduction in 
NOS activity in the intact femoral artery. Thus, inhibition of NOS should 
induce a smaller vascular response in the obese intact limb compared to the 
denervated limb, and widen any difference in FVR present between 
innervated and denervated hmbs observed prior to weight gain.
3) Since interaction between insulin and NOS is also recognized, and 
reduced response to both are observed in the obese, abnormalities in  this 
interaction may occur in the obese and predispose to hypertension. If NOS 
activity mediates vascular relaxation in response to insulin in lean  animals, 
an abnormality in this interaction may occur in obesity. We hypothesize 
tha t a reduction in NOS activity occurs in the obese, reducing insulin's 
ability to induce vascular relaxation, and possibly predisposing to 
hypertension. Hyperinsulinemia in lean animals w ith normal NOS activity 
should reduce vascular resistance, and NOS inhibition in this population 
should decrease the vascular response to hyperinsulinemia if it  is indeed 
mediated through NO activity. However, in the obese, who have reduced
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vascular NOS activity, insulin may be unable to cause vascular relaxation 
when NOS is inhibited, thereby predisposing to pressure/vascular resistance 
increases. Sympathetic activity may also influence this response since it 
may reduce NO activity. Thus, unilateral denervation technique during 
these studies allows the examination of the SNS interaction.
The above hypotheses were studied in canine model of diet-induced 
obesity (Rocchinni et al., 1987) by using the hyperinsulinémie euglycemic 
clamp technique (HIEC; DeFronzo et al., 1979) and NOS inhibition in lean 
and obese animals. The HIEC technique uses a constant rate insulin 
infusion and a variable rate glucose infusion to examine insulin sensitivity 
while maintaining euglycemia (Defronzo et al., 1979). This procedure raises 
plasm a insulin levels acutely and then maintains them at a new plateau 
without the complication of hypoglycemia (Defronzo et al., 1979). Thus, the 
HIEC technique allows one to study physiologic effects of elevated in su l in  
levels (Liang et al., 1982) and determine sensitivity to insulin-mediated 
glucose disposal. The HIEC procedure was performed alone and after NOS 
inhibition to determine whether interaction of insulin and NOS is an 
important predisposing pathway for hypertension in the obese, and whether 
SNS activity influences the response to insulin.
The canine model of diet-induced obesity was used in these studies. 
This model was described by Rocchinni et al. (1987) in a study in which a 
high fat diet was fed for 5 weeks. During overfeeding, the anim als exhibited 
significant weight gain which was associated with elevations in arterial
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pressure, heart rate, plasma volume, cardiac output and systemic vascular 
resistance, as is also described in humans (Alexander et al., 1962; Mujais et 
al., 1982, Rocchini et al., 1989a). Weight gain in the dogs was also 
associated w ith hyperinsulinemia/insulin resistance (Rocchini et al., 1987), 
as described in both obese and non-obese hypertensive humans (Ferrannini 
et al., 1987). Thus, this is an  appropriate model to study the development of 
hypertension with weight gain (Rocchini et al., 1987 and 1989b). In our 
laboratory, this technique has been modified to include a specially 
formulated diet with consistent ingredients, which can be prepared in both 
a  pelleted and powdered formulation. Also, once an  animal refused to 
consume the entire quantity of diet presented, the hquid mixture was fed 
via a gastrostomy tube to ensure the diet was received in its entirety.
Unilateral denervation of one hind limb (left) was utilized in these 
experiments to study the interaction of the SNS and insulin on vascular 
activity, and to provide an intact control within each individual. Removal of 
nerve activity to one limb also allowed us to examine the role of sympathetic 
activity in mediating the response to NOS inhibition and/or 
hyperinsulinemia. Since the studies were performed in both lean and obese 
dogs, we were able to examine whether the interaction of vascular SNS 
activity, insulin and NO activity differed between lean and obese 
individuals.
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CHAPTERS: MATERIALS AND METHODS 
A nim al c a re  an d  p re p a ra tio n :
The interaction of insulin, the sympathetic nervous system and nitric 
oxide (NO) in controlling femoral blood flow, arterial pressure and heart 
rate were examined in the conscious dog using chronically instrum ented 
and unilaterally lumbar denervated animals. These experiments were 
performed in conscious female dogs, spayed, lean and obese, walking slowly 
on a treadmill (<1.61 km/h; 0.44 m/s). All procedures and protocols were 
approved by the Institutional Animal Care and Use Committee prior to 
initiation.
The canine model of diet-induced obesity-related hypertension was 
used in these studies, since these animals display metabohc, hormonal and 
physiologic changes consistent with those observed in obese hypertensive 
humans. These animals, although expensive to instrument and m aintain, 
are an excellent model for studying relationships between hypertension and 
obesity (Rocchinni et al., 1987). Their size allows long term  vascular access 
and telemetry recording w ith minimal stress.
A nim als: Ten 15-21 kg spayed female dogs were purchased from the 
Louisiana State University School of Veterinary Medicine breeding colony. 
This facility is approved for the breeding of animals for research by the 
United S tates Department of Agriculture. All animals were clinically 
healthy prior to use, having negative heartworm antigen tests (Dirofilaria
31
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
32
immitis) and normal clinical chemistry profiles and hematology. The dogs 
were housed in individual stainless steel metabolic cages with epoxy-coated 
aluminum flooring. Each cage was fitted with an individual radiotelemetry 
receiver (Data Sciences International, St. Paul, MN) for remote telemetry 
data collection and storage via computer (IBM 386 computer using 
DataQuest IV system software. D ata Sciences Intl., St. Paul, MN). The 
cages were located in a temperature controlled room (22 ± 1“C) w ith a 
twelve hour light cycle (7:00A.M.-7:00P.M.).
T readm ill acclim ation : The method of walking during the acute 
studies was instituted to mininiize variability between the arteria l flow of 
the 2 pelvic limbs, without the need for anesthesia or tranquilization.
Several different regimes of sedation/tranquilization or general anesthesia 
were explored prior to the use of this method. However, none of these 
protocols provided adequate animal restraint, while allowing the 
measurement of stable femoral blood flow or arterial pressure over the time 
required for completion of the acute HIEC studies. Thus, the stability of 
femoral artery blood flow was assessed while walking, as were heart rate 
(HR) and mean arterial pressure (MAP). Since these parameters were 
found to remain stable while walking, the acute studies were performed 
with the animals slowly walking on a treadmill a t < 1.6 km/h (0.44m/s).
The dogs were acclimated to standing and walking on a treadmill 
(model #1849-01, Quinton Instrument Co., Seattle, WA) prior to beginning
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the studies. The animals were placed on the treadmill, allowed to stand 
quietly, then the treadmill started (<1.6 km/h; 0.44 m/s). The length of time 
spent walking was slowly increased as the dogs began acclimating/relaxing. 
The amount of time required for acclimation depended upon individual 
personality and behavior. The acute studies were not performed until each 
animal walked comfortably on the treadmill.
C hron ic  In s tru m en ta tio n  a n d  su rg ica l p ro ced u res : All animals 
had instrumentation surgically implanted in the following manner:
1. A chronic indwelling jugular catheter was surgically placed for 
vascular access. A hand made sialastic® (Dow Coming, Midland, ME) 
catheter was inserted into the left jugular vein, with the remaining tubing 
tunneled subcutaneously to the cranial-dorsal thoracic region where it was 
connected to a subcutaneous access port.
2. A remote telemetry catheter (Data Sciences International, St. Paul, 
MN) was placed into the left carotid artery  of each animal for continuous 
monitoring of arterial pressure and heart rate. The associated battery unit 
(model# TA11PA-D70) was placed subcutaneously in  the lateral cervical 
region. Each animal was housed in a metabohc cage equipped with its own 
telemetry receiver through which data was collected and transm itted to an 
IBM 386 computer for continuous data collection.
3. A stainless steel peg gastrostomy tube (Associated Technologies 
and Manufacturing Inc., Baton Rouge, LA) was placed into each anim al
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through a ventral midline celiotomy. The tube was exteriorized through the 
ventro-lateral abdominal wall, caudal to the thoracic rib margin.
4. Bilateral ultrasonic transit time perivascular flow probes (model 
4RS, with a CM4B connector, Transonic Systems Inc., Ithaca, NY) were 
positioned around the proximal femoral arteries. The attached cable and 
connector were tunneled subcutaneously to the dorsal mid-cervical region 
and placed in a subcutaneous pocket until exteriorized just prior to the first 
acute experiment. Following exteriorization the cables and connectors were 
placed in a denim collar to prevent destruction. The collar was changed and 
the os flushed routinely with dilute nolvasan solution or antibiotics to 
minimize infection.
During acute protocols, the probe connectors were attached to a T206 
flow meter (Transonic Systems, Inc., Ithaca, NY) and the femoral blood flow 
(FBF) data stored on an IBM S33 personal computer using DATAQ data 
acquisition software (Dataq Instruments, Inc., Akron, OH). Femoral 
vascular resistance was calculated firom flow using FVR=MAP/FBF.
5. Via a ventral midline celiotomy, the animals underwent a 
unilateral surgical lumbar sympathectomy (left side, La-Le) as described for 
humans by Callander et al., 1958. Removal of the La-Le lumbar ganglia in 
dogs has been shown to provide complete sympathetic denervation of the 
pelvic limbs (Carey et al., 1967), and has been used in the dog to study 
femoral blood flow (Crononwett e t al., 1977; Galt, et al., 1991).
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The animals underwent a total of 3 surgical operations. The jugular 
catheter and the telemetry unit were placed during one surgery. The La-Le 
ganghonectomy and gastrostomy tube placement were performed together 
during a separate surgery, and bilateral femoral flow probes were placed on 
yet another occasion. Each pre-surgical and surgical procedure was 
conducted as follows. Following a 12-18 hour fast, each animal was 
premedicated with acepromazine maleate (Promace®; Fort Dodge 
Laboratories, Inc., Fort Dodge, lA: 0.02-0.2 mg/kg, i.m.; 0.3 mg maximum) 
then anesthesia was induced using thiopental sodium (Pentothal®; Abbot 
Laboratories, North Chicago, IL: 4-6 mg/lb, i.v. to effect). Throughout 
surgery the anim als were maintained on 1.5-3% isoflurane inhalant 
anesthesia (Aerrane®; Ohmeda Caribe Inc., Guagama, PR) as individual 
requirements dictated. The animals were placed on circulating w ater 
heating pads to maintain body temperature during surgery and recovery. 
Intra-operative polyionic fluids and antibiotics (Cefazolin®, 1 gram in  fluids) 
were administered.
Analgesics were not required in the postoperative period by any 
animal. However, flunixin meglumine (Banamine®; Fort Dodge 
Laboratories, Inc., Fort Dodge, LA: 1.1 mg/kg, i.m.) was empirically 
administered during the recovery period of the combination 
denervation/gastrostomy surgery, to reduce postoperative inflammation and 
discomfort which may have resulted from visceral manipulations required to 
access the ganghonic chain and perform the La-Le ganghonectomy and  the
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tube-gastrostomy. Antibiotics were administered (TMPS®; Sidmark 
Laboratories, Inc., E ast Hanover, NJ: 30 mg/kg; per os, BID) for a minimum 
of three days following surgery. A minimum of 1-2 weeks of recovery was 
allowed, depending upon the procedure performed, the sequence of the 
surgeries for each animal and their individual recovery rates. AU surgical 
manipulations were performed a t least one week prior to any acute infusion 
study, and a minimum of 2-2.5 weeks was aUowed foUowing denervation 
prior to experimentation. Indwelling catheters were flushed weekly w ith 
heparinized saline (lOOU/ml) to maintain patency.
D iet m an ip u la tio n s: Water was available, free choice, a t all times. 
The animals were initiaUy fed Purina Dog Chow® (21% protein, 49.2% 
carbohydrate, 8% fat, 4.5% fiber) once a day to maintain stable body weight. 
FoUowing weight maintenance on Purina Dog Chow®, and prior to 
beginning the acute studies, a speciaUy formulated peUeted diet was 
introduced (Table 1; total protein 26%, total carbohydrates 62%, to tal fat 
12%). This peUeted diet was fed a t the quantity calculated to provide the 
equivalent number of Kcal of energy provided by the Purina® dog chow 
required during stable weight maintenance. If necessary, the quantity of 
peUeted diet fed was adjusted to maintain stable body weight. The animals 
were weight stable for a  least 1 week prior to the acute lean experiments.
The lean animals were maintained weight stable on the custom peUeted diet 
(Table 1) without additional fat. FoUowing completion of the acute lean
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Table 1: Custom canine diet #D72204. Diet #D72204 was formvdated by 
Research. Diets Inc., New Brunswick, NJ.
Ingredient gm kcal
Casein 200 800
Soy protein 50 200
DL methionine 3 0
Sucrose 175 700
Dextrose 360 1440
Maltodextrin 10 50 200
Cellulose 40 0
Xanthan Gum 10 0
Com Oil 50 450
Salt mix S70003 50 0
Vitamin mix V90001 10 40
Choline bitartrate 2 0
TOTAL 1000 3830
experiments, the lean animals were overfed a powdered formulation of the 
custom diet, to which melted lard was added to increase the energy intake 
to 150% above maintenance. The animals were acclimated to the higher fat 
food by increasing the fat content to 50%, 100% and 150% above 
maintenance levels over several days. The animals initially were allowed to 
eat the diet a t will, then fed via the tube-gastrostomy once their appetite 
waned. This overfeeding paradigm produces significant increases in body 
fat over 5-7 weeks (approximately 25%-50% increase in body weight), 
without the development of intractable diarrhea, vomiting, or pancreatitis. 
All lean animals were weight stable for at least one week prior to the acute 
studies. At the end of the 7-week overfeeding period (during the acute obese 
experiments) each animal was maintained weight stable by feeding the 
powdered-diet and lard mixture to provide 50% above calculated
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
38
maintenance energy requirements. This individual feeding regimen was 
adjusted by adding or reducing the lard content to ensure weight stability 
during the acute post-obesity protocols.
Body w eight, body com position  a n d  MAP/HR m onito ring :
Body weight was measured in the fasted animal three times per week 
throughout the studies. Dual-energy x-ray absorptiometry (DEXA; Hologic 
model QDR-2000, Waltham, MA) was performed in anesthetized animals at 
the end of the lean studies and again prior to the obese protocols. DEXA is 
a technique for directly assessing body composition using dual x-ray beams 
of differing energy levels which are differentially absorbed by tissues 
varying in density (Jensen et al., 1993). Arterial pressure and heart rate 
were monitored continuously via telemetry throughout the pre-obesity 
experimental study period and during the overfeeding period. However, to 
minimize external environmental influences on blood pressure and heart, 
only data collected between 7:00 p.m. and 7:00 a.m. (over-night) was used 
for daily averages.
A nalytical p rocedures:
P lasm a in su lin  rad io im m unoassay : Insulin levels in plasma 
were measured using radioimmunoassay kits purchased from Linco 
Research, Inc. (St. Charles, MO). Canine standards were run  in triplicate 
with each assay, and all subject samples and canine quality controls were 
run in duplicate. All samples from both the lean and obese 
hyperinsulinémie euglycemic clamp (HIEC) and the hyperinsulinémie
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euglycemic clamp performed following nitric oxide synthase inhibition 
(LNA-HIEC) of each anim al were run w ithin one assay (n=2 assays with 
three animals per assay) and weekly samples for all anim als and all weeks 
were run in a single assay. Intra- and inter-assay coefGcients of variation 
were 4% and 7% respectively.
The protocol followed for plasma in sulin determination was the 
standard insulin RIA procedure followed for canine samples in our 
laboratory. In short, 100 pi of standards or samples were separately 
pipetted into borosihcate culture tubes and  100 pi of assay buffer, then 1®‘ 
antibody (guinea pig anti-porcine insulin serum) were added. One hundred 
pi o f  1̂ 25 insulin trace was added to each tube. The samples were incubated 
overnight, then 100 pi of the antibody (goat anti-guinea pig IgG) and 
carrier (normal guinea pig IgG) were added and the samples incubated for 2 
hr a t 4“C. One ml of wash buffer was then  added to stop the reaction and 
all samples were centrifuged a t 3,000 RPM for 25 min a t 4°C. The 
supernatant was carefully poured off and the samples were allowed to dry 
and the activity was determined using a  gamma counter (model 5500B, 
Beckman Instruments Inc., Fullerton, CA).
P lasm a glucose ana ly sis : Plasm a glucose concentrations were 
determined using a YSI model 2700 glucose analyzer (Yellow Springs 
Instruments, Yellow Springs, OH), which utilizes the glucose oxidase 
method. The normal range of plasma glucose concentrations for our 
animals was 90-108 mg/dl, for studies 3 and 4 combined.
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T issue  ca techo lam ine  levels: At the termination, of all studies, 
femoral artery  sections (3-4 artery sections per limb) were removed and 
tissue catecholamine levels assessed. Femoral artery tissue samples were 
recovered immediately from the animals following euthanasia. Left limb 
(denervated) samples were taken first to reduce the chance of lowering 
quantities of catecholamines due to the rapid metabolism. The samples 
were placed into chilled 0.1 M perchloric acid and immediately frozen in 
hquid nitrogen. During the homogenization procedure a total of 1.5 m l of 
perchloric acid was added to the volume during flushing of tubes. Tissue 
homogenization was performed on the same day as collection in all bu t one 
animal, using a tissue homogenizer from Omni Inc (Warrenton, VA). In  this 
animal the homogenizer broke at the start of the first sample so 
homogenization was postponed until a replacement was obtained (8 days).
Tissue homogenates were assayed using high performance liquid 
chromatography (HPLC) to determine tissue catecholamine levels. These 
assays were performed by Dr. Gennady Smagin using the standard 
techniques of his laboratory. In short, tissue homogenate supernatant (0.5 
ml) was extracted using 50 mg acid washed alumina and TRIS buffer/EDTA 
(1.5 M, pH 8.6). Samples were analyzed (50 pi injection volume) for 
neurotransm itter (NE and E) concentration using an HPLC system 
consisting of a pump (model 420), autosampler (model 460), Coulochem 
detector (model 5100A), high performance analytical cell (model 5014), and 
MD-150 column (all from ESA, Inc. Bedford, MA). The mobile phase
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consisted of 75 mM NaH2P04, 1.4 mM l-octenesulfonic acid sodium salt 
monohydrate (OSA), 10 |iM EDTA, 10% acetonitrile adjusted to pH 3.1 with 
H 3PO4 . The flow rate was maintained at 0.9 ml/min. Minor changes of pH 
and OSA concentration were made to obtain optimal separation. Detector 
potentials were set a t -0.04 V for electrode 1, +0.35 V for electrode 2 and a t 
+0.4 V for the guard cell. Data were collected by a Kontron IBM-PC-based 
integrator (ESA, Inc, Bedford, MA), and the integrated data were 
transferred directly to a spreadsheet program for data analysis.
Appropriate extracted catecholamine standards were prepared 
(NE/arterenol and E/adrenalin, Sigma, St. Louis, MO) and ru n  (150 pi 
injection volume containing 2.14 ng of NE and E) with the samples. All 
samples for each animal were run  within the same assay. The laboratory 
inter-assay coefficient of variation for the catecholamine HPLC assay is 
<5%. Before samples were processed, assay vahdation was performed. This 
validation was performed by extraction of 100, 50, 25, 10, 5, and 0 ng/ml of 
NE. N-methyl-D-aspartate (NMDA) was used as the internal standard.
The peak height of NE was measured and the ratio of NE to the internal 
standard was determined. This ratio should remain constant a t varying 
concentrations, and the linearity of the ratio was checked for validation.
Once linearity was validated, samples were analyzed, with single point 
calibrations (using lOng/ml of NE) used for daily quantitation of samples as 
long as no system components were changed. The concentration of NE in
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the samples were in the range of 1-10 ng/ml of extract, and within the 
validated linear range.
A cu te  ex p erim en ta l protocols:
All acute experiments were performed in lean fasted anim als (12-18 
hour fast) and repeated in the same animals after seven weeks of 
overfeeding. Heart rate (HR), arterial pressure (BP) and femoral blood flow 
(FBF; used to calculate femoral vascular resistance, FVR) were measured 
throughout the studies. Following a 5-10 minute acclimation period, twenty 
m inutes of walking baseline data were obtained a t the beginning of all 
experimental studies. The drug doses calculated for these studies were 
based upon the weight of each dog on the date of the study (i.e. lean wt. or 
obese wt.). If necessary, a study was repeated based on data work-up, or if 
stable glucose levels could not be achieved within 120 min of initiating the 
hyperinsulinémie euglycemic clamp (HIEC) for studies 3 and 4.
S tu d y  1: Time course  for th e  developm ent o f  v ascu la r re s is ta n c e  
ch an g es  and  in su lin  res is tan ce  w ith  obesity . To determine the time 
course of vascular resistance changes with the development of obesity, and 
w hether these changes occur concurrent with changes in insulin levels, we 
monitored fasting insulin levels and vascular resistance changes throughout 
the development of obesity. Prior to and during the 7-week period of 
overfeeding, 10 ml of blood was obtained weekly from each animal, in the 
fasted state. On the same day blood was drawn, the a n i m a l s  were placed 
onto the treadmill (<1.6 km/h; 0.44 m/s) and 30 min of BP/HR/FBF data
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were recorded (10 min acclimation and 20 min of stable recordings).
Changes in arterial pressure, heart rate, FVR and fasting insulin were 
compared prior to the sta rt of overfeeding and weekly throughout the 
development of diet-induced obesity.
S tu d y  2: C ard io v ascu la r p a ra m e te rs  fo llow ing  NOS in h ib itio n  w ith  
LNA. Once 20 min of stable baseline data  was collected, 10 mg/kg of nitro- 
L-arginine (LNA; a competitive inhibitor of nitric oxide synthase; Aldrich 
Chemical Co., Inc., Milwaukee, WI) was administered through the 
indwelling jugular vein port. Walking on the treadmill (<1.6 km/h; 0.44 
m/s) was continued for 2 hours following LNA adm inistration while 
continuously recording BP/HR/FBF. At the end of this study, L-arginine 
(bolus dose of 150 mg/kg, iv) was administered to reverse the lasting effects 
of LNA (Eisner et al., 1994). Nonetheless, a  minimum of 5-7 days was 
allowed for recovery of BP/HR/FBF response subsequent to LNA studies. 
S tu d y  3: T he h y p erin su lin ém ie  eug lycem ic  clam p (HIEC) in  le an  
an d  obese dogs. Once stable baseline walking cardiovascular data was 
collected, a hyperinsulinemic-euglycemic clamp procedure (HIEC; DeFronzo 
et al., 1979) was performed in each anim al in  the following manner. During 
the 20 min walking baseline period blood samples were obtained a t -15, -10 
and -5 min (1-1.5 ml obtained through the jugular access port), placed into a 
heparinized micro-centrifuge tube and centrifuged to separate plasm a and 
cells. The plasma was immediately analyzed for glucose concentration (YSI 
glucose analyzer model 2700, Yellow Springs Instrum ents, Yellow Springs,
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OH), and the remaining plasma was stored for insulin assay by RIA. The 
average of the -15,-10 and -5 min glucose samples was used as the baseline 
value for th a t animal, and the ± 5% glucose range was calculated. The 
infusion lines were primed with both insulin and glucose. At t=-5 m in  the 
insulin infusion was begun at a priming rate of 1.5 ml/min for 5 min. At the 
t=0 point, the insulin infusion rate was reduced to 1.0 m l/m in  for an 
additional 2 min, and a t t=2 min, the rate was set to 0.5 m l/m in  in s u lin  (40 
mU/min) for the remainder of the study. Glucose (30% solution in sterile 
water) was concurrently administered at an initial priming rate  of 1.0 
ml/min for 1 min (starting a t t= -l min). At t=0, the glucose rate was 
reduced to 0.5 ml/min and adjusted as necessary thereafter to m a in ta in  
plasma glucose levels w ithin a ± 5% range of the baseline average. Both 
insulin and glucose infusions were administered through a cephalic vein 
catheter using syringe pumps (model #22, Harvard Apparatus, Southnatick, 
MA). Blood samples (1.0-1.5 ml) were obtained every 5 m inutes from the 
jugular access ports to monitor plasma glucose concentration, allowing 
adjustment of the glucose infusion rate to m aintain euglycemia (90-108 
mg/dl). The remaining plasma was saved for in s u lin  assay.
Once glucose was stabilized within 5% of baseline, FBF/BP/HR data 
were collected for 2 0 -3 0  min while the an im al continued a  slow walk (< 0 .4 4  
m/s). Each study ended when 5-7  consecutive stable glucose samples were 
obtained th a t were within the ± 5% baseline range. This allowed a 
minimum of 3 0 -3 5  min of data collection while glucose was w ithin 5% of the
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baseline. Thus, the most stable 20 min could be used for statistical 
comparison.
During the HIEC protocols (alone and under NO inhibition) 25 lU / ml 
of heparinized saline (2.5 ml) was flushed through the sampling lines 
following sample withdrawal. Prior to all sample withdrawals, 2.0 ml of 
flush/blood mixture was withdrawn from the sampling line and discarded. 
Another 3 ml of blood was removed to ensure th a t no flush remained in the 
collection line. The 1.5 ml blood sample to be used for glucose and insulin 
analysis was then withdrawn, the initial 3 ml was returned to the animal 
and the Hne was flushed w ith 2.5-3.0 ml of heparinized-saline solution (25 
lU/ml). Thus, in these extended length protocols, the maximum amount of 
heparin administered was approximately 25-40 mg for the 2+ hour studies. 
The higher level is within the recommended initial loading dose for 
anticoagulant therapy with heparin in dogs. Removal and discarding of the 
initial 2.0 ml of blood before sampling made the actual amount of heparin 
remaining within the animal significantly less than that calculated. These 
steps were teiken to reduce any possible effects tha t may occur in fatty acid 
metabohsm or hepatic clearance resulting from elevated levels of heparin.
No signs of coagulation defects were observed following any protocol. The 
maximum volume of blood withdrawn from any individual was 
approximately 40-50 ml (for a study lasting a  full two hours). This volume 
was neghgible in this size dog, especially in light of the fluids being replaced 
w ith the insulin and glucose infusions.
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Both, glucose and insulin infusions were administered through a 
cephalic vein catheter, and the blood samples were obtained through the 
jugular access port. At the termination of each study, the plasma samples 
were frozen at -20°C until assayed for insulin. A minimum of 48 h r was 
allowed between any HIEC study and another study.
S tu d y  4: The HIEC follow ing n itr ic  oxide sy n th a se  in h ib itio n  (LNA- 
HIEC) in  lean  a n d  obese dogs. These studies were carried out exactly as 
for the HIEC previously described in Study 3, with the following additions. 
Once baseline walking cardiovascular data were collected, the treadm ill was 
halted and nitro-L-argine (LNA; a competitive inhibitor of nitric oxide 
synthase; Aldrich Chemical Co., Inc., Milwaukee, Wl; 10 mg/kg, iv) was 
administered. The dogs were allowed to stand or sit a t will for 45 m in, 
while waiting for cardiovascular parameters to change and stabilize 
following LNA administration. The treadmill was then  restarted (<1.6 
km/h; 0.44 m/s) and another walking baseline was obtained under the 
influence of NOS inhibition. During this stable 20 minute baseline of LNA- 
walking, the -15,-10 and -5 min baseline glucose/insulin blood samples were 
collected from the jugular catheter access port, as described in the original 
clamp protocol. Thereafter, the HIEC protocol was performed exactly as 
described for Study 3 [i.e. initial priming of both insulin and glucose 
followed by a constant insulin infusion of 0.5 ml/min (40 mU/min) an d a 
variable glucose infusion rate adjusted to maintain euglycemia]. A
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minimum of 5-7 days was allowed between any LNA study and another 
study.
Statistical analysis:
All statistical analyses were performed by the Biostatistics 
Departm ent of the Pennington Biomedical Research Center, using PROC 
MIXED or PROC GLM in BAS, version 6.12. In  all multiple comparisons, p- 
values were adjusted with respect to Tukey-Kramer or Bonferroni 
inequalities as specified below.
Body composition was analyzed using univariate analyses (t-test on 
the leanrobese difference) comparing lean and obese DEXA scan results. 
Change in body weight with overfeeding was analyzed with a mixed 
statistical model and autoregressive covariate structure (assuming equal 
week to week variances and thereby reducing the number of unknown 
param eters in the model), with baseline weight as a covariate in the model. 
Body weight was the dependent variable in the model, regressed over tim e 
in weeks. Additionally, the weekly change compared to baseline was 
assessed using the same model structure, w ith the difference in weight 
between each week and the baseline as the dependent variable and time 
(week) as the fixed effect.
The change in insulin during the overfeeding period (main effect of 
time in  weeks) was analyzed using a mixed model with weekly in s u lin  
concentration as the dependent variable regressed over time (in weeks), for 
7 dogs and over 8 weeks. In  addition, the change in insulin concentration
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ôrom baseline for each, week of overfeeding was analyzed using a mixed 
model w ith an autoregressive covariate structure (a s s u m in g  equal week to 
week variances to reduce the number of unknowns in the model) for 7 dogs 
and 7 baseline to week differences (the dependent variable was the 
difference in in su lin  between baseline and each week of overfeeding, with 
week as the fixed effect in the model). Other weekly data (MAP, HR and 
FVR) were analyzed in a similar manner, determining the main effect of 
time as well as weekly change. For aU of these weekly parameters, if the 
baseline parameter measure was determined to be a significant covariate in 
the model, it was included as such. For FVR, combined data were analyzed 
to determine whether differences between the limbs (denervated and intact) 
developed over time for either position (standing and walking ). Then, each 
limb was analyzed separately, for each position, for main effect of time and 
weekly difference firom baseline. The positions and limbs were analyzed in 
this way (separately) due to the complexity of the model when all variables 
were included together. Correlation analyses (insulin with weight, HR,
MAP and FVR [intact and DNX]) were performed for each an im al and the 
group.
In the study examining cardiovascular param eters and stabilization 
following LNA (Study 2) data were analyzed using the mixed model with 
autoregressive structure and baseline parameter level as a covariate, to 
determine whether each parameter showed a significant time effect after 
LNA administration (model variables of weight group-lean and obese).
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Once it was determined that the cardiovascular parameters remained stable 
following acclimation to treatm ent with LNA, all post-LNA data points were 
combined for pre-LNA and post-LNA comparisons and for the analysis of 
differences in response between weight groups. The dependent variable in 
this mixed model was the difference between pre-LNA and post-LNA 
param eters of HR and MAP for 6 dogs and comparing two weight groups 
(lean and obese). This model used an unstructured covariate design (does 
not assume equal variances of the covariate matrix thus) w ith weight group 
and treatm ent period as the fixed effects, covariate param eter estimation 
and Tukey-Kramer adjustment for multiple comparisons. For FVR, the 
difference between the two limbs was assessed, then the individual limb 
response to treatm ent was separately analyzed and weight groups 
compared, due to the complexity of the model and the number of 
variables/sources of error. In these analyses, weight group, limb (intact or 
DNX) and treatm ent period were the fixed effects in the model
In the HIEC and LNA-HIEC studies (Studies 3 and 4), the difference 
in response between the two studies in both weight groups was analyzed 
with each param eter as a dependent variable (HR, MAP, DNX-FVR, intact- 
FVR), and an unstructured covariate structure with fixed effects and 
covariate param eter estimation. Data were analyzed for two weight groups, 
LNA-HIEC and HIEC studies and n=6 dogs. In addition, the differences in 
response to treatm ent (difference between baseline and hyperinsulinemia) 
between weight groups were analyzed for each study separately, again
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using a mixed model with unstructured covariate design (as described 
above), covariate param eter estimation and Bonferroni adjustm ent for 
multiple comparisons.
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CHAPTER 4: RESULTS
Ten animals were originally instrumented for inclusion in these 
studies. However, only 7 animals finished the overfeeding regimen, and  6 
finished all obese acute experiments, due to unilateral or bilateral femoral 
flow probe failure.
The weekly body weight of the dogs increased significantly during the 
7-week overfeeding period (Figure 2; Table 2). Although lean body mass 
(LBM) did not change significantly with overfeeding, the total grams of fat, 
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W eek of Overfeeding
“ Data are group means ±  standard error of the mean (SEM) for n=7 dogs.
* Significantly different from baseline, p<0.01.
Figure 2; Change in body weight over the 7-week overfeeding period. ®
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Table 2: Body composition prior to (Lean) and following (Obese) 7 weeks of 
o v e r f e e d i n g . ® ___________ _____________  _____
■
B ody w eigh t (kg) 19.9 ± 0.7 29.7 ±  0.77 <0.001
B ody fa t (kg) 4.53 ± 0.84 14.64 ±  0.81 <0.001
% Body F a t 23.0 ± 3.65 48.8 ±  1.95 <0.001
LBM (kg) 14.39 ± 0.63 14.73 ± 0.49 ns
BMC (kg) 0.53 ± 0.02 0.57 ±  0.02 p=0.01
“ Data are group means (n=7) ± standard error of the mean (SEM). 
ns = not significant
Postmortem femoral artery norepinephrine levels of the obese dogs
were significantly different between the denervated (270.13 ± 90.5 ng/g) and
intact (627.3 ± 108 ng/g; p=0.028) limb femoral arteries. This confirms
reduced femoral artery catecholamine levels (as a reflection of SNS activity)
in  the denervated femoral artery during post-obesity studies.
Study 1: Time course for the development of vascular resistance 
changes and insulin resistance with obesity.
In this study, weekly comparisons of MAP, HR and FVR were made 
with the animals standing and walking on the treadmill. Fasting plasma 
insulin levels were also assessed. There was a significant increase in MAP 
over the 7-week period of overfeeding (significant main effect of time; Figure 
3) in both the standing (p=0.022) and walking positions (p=0.022).
However, using direct week to baseline comparisons, only the MAP in week 
7 (standing) did the difference firom baseline approach significance 
(p=0.056).
Heart rate also increased over the 7-weeks of overfeeding (significant 
main effect of time, p=0.008; Figure 4). However, only in week seven was 
the HR significantly increased over baseline while walking ^=0.012).
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H eart rate during week 1 decreased significantly compared to baseline 
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* Significantly different firom baseline, p<0.05. Values are group means ± SEM; n=7. 
Figure 4: Heart rate during the 7-week overfeeding period.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
54
There was a significant overall time effect on FVR in the standing 
(p=0.0407) and walking ^=0.0001) positions (Figure 5) for the denervated 
and intact Hmbs. Standing FVR of the denervated limb was significantly 
greater than baseline during weeks 1-2 of overfeeding, whereas FVR of the 
intact limb was significantly greater than baseline in weeks 1-5 (Figure 5). 
In the walking state, both the denervated (p=0.0173) and intact limbs 
(p=0.0074) showed a significant time effect of high-fat feeding. However, 
compared with baseline walking FVR, only the intact limb showed 



















• o -  Standing-Intact 
Walking -DNX 
- a -  Walking-intact
Base 2 3 4  5
Week of Overfeeding
* Significantly different from baseHne,*p<0.05; **p<0.01. Data are group mean ± SEM, n=7.
Figure 5: Femoral vascular resistance during the 7-week overfeeding 
period-
Fasting plasma insulin levels increased significantly during the 
overfeeding period (main effect of time, p=0-04; Figure 6). Baseline insulin
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concentration ranged from 5.0-12.4 lU/ml in these dogs, with a significant 
increase from baseline observed by week 2 of overfeeding Op=0.04).
However, significant correlation between insulin and the cardiovascular 
parameters was not observed, and a very weak correlation of insulin with 
body weight was present (r=0.346; p=0.0161). Only weak correlation was 
evident between body weight and cardiovascular param eters (MAP: 
r=0.314, p=0.0281; HR: r=0.378, p=0.0075; DNX-FVR: r=-0.295, p=0.0398; 
intact- FVR: r=-0.295, p=0.052). The strongest correlation present was a 
negative correlation between heart rate and FVR of both limbs (DNX limb r 









Base 1 2 3 4 5
Week of Overfeeding
* Significantly different firom baseline,*p<0.05;**p<0.01. Data are group mean ± SEM, n=7.
Figure 6: Weekly fasting plasma insulin levels during the overfeeding 
period.
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Study 2: Cardiovascular parameters following NOS inhibition with 
LNA.
Following the initial response to LNA, all param eters (MAP, HR and 
FVR) stabilized following NOS inhibition (Figures 7, 8, and 10). Thus, the 
post-LNA treatm ent data were averaged for statistical comparisons, as were 
data from the twenty minute pre-LNA period.
Mean arterial pressure did not differ between lean and obese dogs 
during the pre-LNA (20 min average for lean, 97 ± 10 mmHg; obese, 107 ±
3.0 mmHg) or post-LNA treatment periods (lean, 115 ± 1.5 mmHg; obese,
123 ± 0.65 mmHg). Following LNA administration, MAP increased 
significantly and stabilized in both weight groups (Figure 7). The MAP 
response to LNA did not differ between the weight groups.
1 4 0  Lean
1 3 0  O b ese
120 -
I—'O—O— —o—o
I  / f  » .  — " " .  .  _
5  100  /
® 90 - -A
80 LNA
7 0  '----------------------- :----------:------------------- :-----:-----:-----:---- '-----:-----:---------- :-------
-20 -10 35 60 90 120
Minutes Post-LNA
“ Data are group means (n=6) ± SEM.
* Significant increase following LNA treatment (using a  20 m in  average of pre-LNA period 
and a 90 min average of the post-LNA period),*p<0.05; **p<0.01.
Figure 7: MAP response to NOS inhibition in lean and obese dogs.®
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H eart rate (Figure 8) differed significantly between the lean and 
obese dogs during the pre-LNA period ^=0.0007; 20 min average for 
lean=107 ± 4 BPM, and obese=130 ± 4 BPM) and post-LNA period 
(p=0.0001; 90 min average for lean, 75 ± 1 BPM; obese, 107 ± 1 BPM). 
Although HR decreased significantly in both weight groups following NOS 
inhibition, p<0.01 for each (Figure 8), the HR response to LNA 
administration was attenuated in the obese animals (Figure 9; p=0.02 for 32 
BPM average HR decrease in the lean and the 24 BPM reduction in HR for 
the obese).
150 " #
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50  ---------------  :--------:------------------- :----------- -̂-- :------
-20 -10 35 60 90 120
Minutes Post-LNA
® All values are group means (n=6) ± SEM.
** Significant decrease following LNA treatment, p<0.01.
# Significant difference between lean and obese (using a 2 0  m in  average of pre-LNA period 
and a 9 0  min average of the post-LNA period), p<0.01.
Figure 8: Heart rate response to NOS inhibition in lean and obese dogs.®











‘Significantly different from lean, p<0.05.
Data are group means ± SEM for n=6 dogs.
Figure 9: Change in heart rate following LNA adm inistration
Pre-LNA femoral vascular resistance did not differ between the lean 
and obese dogs (Figure 10). Also, pre-LNA FVR did not differ in the DNX 
and intact limbs in either weight groups. However, following LNA 
administration FVR differed between the weight groups (p=0.0086 for main 
effect of weight), and between the intact and denervated limbs (p=0.0048, 
for main effect of hmb). Femoral vascular resistance increased significantly 
in both the DNX and intact limbs of the lean animals following LNA 
administration (DNX, p= 0.01; intact, p=0.02). The increase in FVR in the 
obese group did not quite reach significance (DNX, p=0.06; intact, p=0.051). 
In the lean animals during the post-LNA period, DNX limb FVR was 
significantly higher compared to the intact limb (p=0.002; Figure 10).
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However, this was not so in the obese. Additionally, FVR in the denervated 
limb of the lean dogs was higher than  the obese during the Post-LNA period 
(p=0.02; Figure 10). Thus, the FVR response following LNA administration 
was significantly different between the lean and obese dogs Op=0.0135).
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** Increase in FVR following LNA significantly different between intact and DNX limbs of 
the lean animals, p<0.01 (comparing 90 min averages of the post-LNA treatm ent periods for 
n=6 dogs).
#  Significant difference between DNX limb FVR of lean and obese dogs, p<0.05 (comparing 
the 90 min averages of the post-LNA treatment period for n=6 dogs).
Figure 10: Femoral vascular (FVR) response to NOS inhibition in lean and 
obese dogs.
Studies 3 and 4: The hyperinsulinémie euglycemic clamp, alone 
(HIEC) and following NOS inhibition with LNA (LNA-HIEC).
Glucose levels were not significantly different between the lean and
obese animals during the walking baseline period or during the stable
euglycemic hyperinsulinémie period in either study (Table 4). During the
stable hyperinsulinémie euglycemic period of the HIEC study, the glucose
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infusion rate of the lean a n im a ls  was a lm o s t twice that of the obese (GER**- 
HIEC; Table 3). In the LNA-HIEC, during which NOS was inhibited prior 
to the HIEC, the lean-obese difference in  glucose infusion ra te  was not 
evident (GIR‘’-LNA-HIEC). In the obese, the difference in GIR between the 
two studies was minimal (obese GIR*’-HIEC vs. obese GIR^-LNA-HIEC; 
Table).
Table 3: Plasma glucose» levels in lean and obese dogs during the HIEC and 
LNA-HIEC studies.
■ I
Pre-H IEC 99.0 ± 1.63 98.7 db0.73
H IEC 96.9 ± 2.91 99.1 ± 1.28
Pre-LNA-HIEC 97.4 ± 1.97 99.4 ± 2.21
LNA-HIEC 98.2 ± 2.57 97.7 ± 2.33
GIRb-HIEC 0.45 ± 0.12 0.26 ± 0.09*
GIRb-LNA-HIEC 0.31 ± 0.09 0.30 ± 1.0
“ Glucose levels in mg/dl; group mean (n=6) ± standard error of the mean (SEM).
GIR; glucose infusion rate during stable euglycemic period in ml/min 
* Significant difference between lean and obese, p<0.05.
Baseline insulin, combining both the HIEC and LNA-HIEC studies, 
was higher in the obese an im a ls  (p=0.0228; Table 4). However, the 
difference in baseline (Pre-Clamp) insulin levels between the lean and obese 
animals in the HIEC study did not reach significance (Table 4), and the Pre- 
Clamp difference in lean vs. obese insulin for the LNA-HIEC study 
approached significance (p=0.053). Baseline insulin levels did not differ 
between the HIEC and LNA-HIEC studies. The increase in  insulin 
observed during the stable hyperinsulinémie euglycemic period (Table 4; 
Stable-Clamp) was significant, for both weight groups and both studies 
(p<0.05).
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Table 4: Insulin^ levels during the EŒEC and LNA-HIEC studies.
m tm
WÊÊÊ
Pre-C lam p L e a n t 5.8 ±  1.02 3.7 ± 0.82*
S table-C lam p Lean 31.9 ±  6.80# 39.3 ± 15.0#
Pre-Clamp*» Obese 24.9 ± 8.55 16.72 ± 3.89
S table-C lam p Obese 48.6 ± 15.7# 50.6 ± 11.6#
J ^ C L t f C t  A X 1 .C C U X O  ^  O M X X X U C L L \X  C X X V X  L X I C  A i X C d l l  \ K J J U J , r ± / ,
Pre-Clamp period for the  LNA-HIEC study was post LNA administration.
* S ig n ifica n tly  different &om Pre-ciamp insulin value of the obese an im a ls  in  same study 
(LNA-HIEC). p=0.053.
 ̂Difference &om Pre-ciamp insulin value is significant (within the same weight group and 
study), p<0.05.
t  Significant difference in Lean Pre-ciamp insulin compared to obese Preciamp in s u lin , for 
both studies combined, p<0.05.
Mean arteria l pressure during the HIEC was not different from that 
of the LNA-HIEC studies, in either the lean or obese dogs (Figure 11, 
p=0.0857). Hyperinsulinemia did not significantly alter MAP in either 
weight group in the  HIEC (Pre-HIEC vs. Post-HIEC) or LNA-HIEC studies 
(LNA-Pre-HIEC vs. LNA-Post-HIEC). However, in the LNA-HIEC study, 
the lean animals showed a trend toward reduction in MAP during 
hyperinsulinemia, while the obese dogs tended to increase MAP (p=0.03 
unadjusted for multiple comparisons) when the HIEC was performed after 
NOS inhibition.
Analysis of the data collected during the HIEC and LNA-HIEC 
studies revealed th a t heart rate (Figure 12) was affected by weight group 
and NOS inhibition, but was not affected by hyperinsulinemia. The average 
difference in HR between the HIEC and LNA-HIEC studies was greater in 
the lean animals (38 BPM) compared to the obese (27 BPM), p=0.0004.
Also, the difference in heart rate between the lean and obese a n im a ls  was





















Data are groups means ±  SEM obtained during a stable 20 min baseline period before the 
HIEC (Pre-HIEC or LNA-Pre-HIEC) and during the 20 min stable euglycemic period (Post- 
HIEC or Post-LNA-HIEC).
Figure 11: MAP response to hyperinsulinemia alone (HIEC) or during NOS 
inhibition (LNA-HIEC).
significantly influenced by whether it was measured during the HIEC study 
(lean-obese diflerence=27 BPM) or during the LNA- HIEC study (difference 
between lean and obese=36 BPM), p=0.0169. During the HIEC study, the 
difference in heart rate between the lean and obese weight groups was not 
significant. However, in the LNA-HIEC study, HR was significantly higher 
in the obese (p=0.0049; Figure 12) during both the LNA-Pre-HIEC (p=0.01) 
and the LNA-Post-HIEC (p=0.04) periods. Although, the HR differed
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between the lean and obese during LNA-HTEC study, this difference was 
evident prior to LNA administration (p=0.0444; Figure 13), and heart rate 





































L N A -P re-H IE C LNA-Post-HIEC
* Significantly difierent from lean animals during the same study period, p<0.01.
Data are group means ± SEM during a stable 20 min baseline period before the HIEC (Pre- 
HIEC or LNA-Pre-HIEC) and during the 20 min stable euglycemic period (Post-HIEC or 
LNA-Post-HIEC).
Figure 12: H eart rate response to hyperinsulinemia alone (HIEC) or during 
NOS inhibition (LNA-HIEC).























a-b.c Columns with, dissimilar superscripts denote significant differences between group 
means, p<0.G5. Columns with matching letters are not significantly different. Data are 
group means (n=6) ± SEM.
Figure 13: Heart Rate response to LNA administration during the LNA- 
HIEC study
The difference in hind limb FVR between the HIEC and LNA-HIEC 
studies was influenced by weight group (DNX, p=0.055; intact, p=0.0419 
main effect of weight group) and NOS inhibitory status (DNX, p=0.052; 
intact, p=0.017 for main effect of LNA treatment). However, there was no 
overall difference in  FVR response to acute hyperinsulinemia between the 
intact and DNX limbs in either study, for either weight group. Although the 
obese animals had lower FVR compared to the lean dogs during both 
studies, the difference in FVR between the lean and obese only reached 
significance in the LNA-HIEC study (p=0.046; Figure 14). During the LNA- 
HIEC study, FVR was slightly higher than  that observed during the HIEC
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study. However, only in the denervated limb of the obese a n im a ls  did the 
difference in FVR between the HIEC and the LNA-HIEC studies reach 




















“••• Significant difference in hind limb FVR between lean and obese during the LNA-HIEC 
study, p<0.05.
Data are groups means ±  SEM obtained during a stable 20 m in  baseline period before the 
HIEC (Pre-HIEC or LNA-Pre-HIEC) and during the 20 min stable euglycemic period. (Post- 
HIEC or Post-LNA-HIEC).
Figure 14: Femoral vascular response to hyperinsulinemia alone (HIEC) or 
during NOS inhibition (LNA-HIEC).
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Overall DNX-FVR of the obese dogs is significantly different between HIEC and LNA- 
HIEC studies, p<0.05.
Data are groups means (n=6) ±  SEM obtained during a stable 20 min period before (Pre- 
Clamp) or during the 20 min stable euglycemic period (Post-Clamp).
Figure 15: Difference in denervated limb FVR of the obese dogs during the 
HIEC and LNA-HIEC studies.
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CHAPTER 5: DISCUSSION
The results of these studies suggest that, contrary to our original 
hypothesis, FVR increases immediately with weight gain. However, with 
continued weight gain, vascular resistance returns to baseline levels and 
may drop below baseline levels. This vascular response may be influenced 
by sympathetic activity, since the reduction in FVR observed with continued 
weight gain occurred more rapidly in the denervated hind limb.
Additionally, these studies identify a  difference in cardiovascular response 
to LNA administration (NOS inhibition) between lean and obese dogs. This 
response is suggestive of a reduction in NOS activity in  the obese. Finally, 
our data suggest that nitric oxide activity mediates insulin sensitivity.
As has previously been reported in dogs (Rocchini et al., 1987; Truett 
e t al., 1996), overfeeding of a high-fat diet caused significant weight gain in 
our animals. Consistent with our previous studies in  which DEXA analysis 
was employed (Truett et al., 1996), this weight gain was associated 
primarily with an  increase in fat deposition, although increased bone 
mineral content (BMC) was identified. However, it is unlikely that the 
marked change in BMC is the result of weight-induced bone remodeling, but 
rather was a  limitation/artifact of the DEXA measuring technique. Similar 
artifacts have been reported when m easuring BMC in humans, and are 
likely the result of beam hardening a t extremes of tissue thickness and 
composition (Tothill and Pye, 1994; Tothill and Avanell, 1994; Jebb et al., 
1993).
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Study 1: Time course for the development of vascular resistance 
changes and insulin resistance with obesity.
Although we observed a significant time effect of overfeeding on MAP 
(measured weekly while on the treadmill; Figure 2), only in week 7 did the 
increase differ significantly firom baseline. This elevation in MAP was 
shghtly delayed in onset compared to our previous work (Truett et al.,
1996), and may have been influenced by the presence of the Ls-Le 
ganglionectomy or exercise.
In 1991, Galt and Cronenwett reported a reduction in the MAP of 
anesthetized dogs in which unilateral lumbar sympathectomy procedures 
had been performed. However, an  earher report by this same group did not 
identify significant reduction in MAP with ganglionectomy (Cronenwett and 
Lindenauer, 1977). In neither case were the animals followed chronically 
in the conscious state to determine whether the change in MAP was 
persistent. Another chronic study using conscious dogs did not report MAP 
measurements (Lee et al., 1971). Thus, data in the literature is unclear, 
and it is possible that the unilateral paravertebral ganglionectomy in our 
study may have delayed the elevation of MAP with weight gain.
Another factor which may have influenced the development of 
hypertension in these animals (though an unlikely factor) was the weekly 
exercise regimen (walking <1.6 km/hr [0.44 m/s]; 30 min/week). Moderate 
exercise is known to reduce arterial pressure in humans (Jennings et al., 
1984 and 1986; KingweU et al., 1993; Pescatello et al., 1991). Most hum an
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studies describe moderate exercise paradigms as 30-45 min of exercise three 
times per week, while maintaining approximately 60% Workmax. (Jennings 
et al-,1984 and 1986; KingweU and Jennings, 1993) or 70-80% Vozmax.
(Rogers et al., 1996). In  the study by Rogers et al. (1996), low-intensity 
exercise training (40-50% Vozmax, 3 times/wk) was reported to be a  more 
effective stimulus in reducing resting arterial pressure and blood pressure 
responses to stress than  was moderate-intensity exercise (70-80% Vozmax) in 
borderline hypertensive humans. Although this study reported a  pressure- 
reducing benefit of exercise in humans, the exercise level, even in the low- 
intensity paradigm, was much more intense than  tha t used in our weekly 
canine regimen. Thus, based upon human work, it is unlikely th a t the level 
of exercise provided by the weekly 30 min walking regimen was responsible 
for the delay in onset of elevated MAP in our dogs.
By comparison, O’Leary et al., (1997) used 8 km/hr with a 15% grade 
as a moderate exercise regimen in dogs. Mild exercise was described as 3.2 
km/h a t 0% grade in th a t study, while 4 km/h with a 13% grade, was used 
as a “mild” exercise regimen in dogs in a  study examining systemic and 
regional blood flow at various exercise intensities (Pagny et al., 1986). The 
dogs in our studies walked slowly on a  treadmill during the weekly studies 
a t a speed less than <1.6 km/h, w ith zero grade. According to heart rate and 
oxygen consumption data previously observed in response to treadm ill 
exercise in dogs (CerreteUi et al., 1964), the workload of our dogs, even a t 
the highest average HR (week 7 walking HR =129 ± 8.4 BPM) corresponds
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to less than  25% V0 2  max. if assessed using the graph presented in the 
CerreteUi study. Thus, the exercise level of our dogs was considerably less 
than  th a t used in  mild or low intensity exercise regimens in other canine 
studies, and one would not expect the exercise program to have influenced 
chronic MAP measurements.
Our study examining changes in vascular resistance w ith weight gain 
appear to indicate th a t femoral artery  vascular resistance increases 
immediately foUowing overfeeding/weight gain, and a reduction in FVR 
ensues with continued weight increase. These vascular changes may be 
influenced by autonomic nervous system input, as the reduction in FVR 
occurred earher in  the limb in which a lumbar sympathetic ganghonectomy 
was present. Systemic vascular resistance has been reported to be higher 
(Rocchini et al., 1987) and total peripheral resistance (TPR) reported to be 
lower than normal in obese dogs (MizeUe et al., 1994; Hall et al., 1995). 
MizeUe et al. reported an initial reduction in TPR foUowed by a trend 
toward, but not reaching, normal levels by week 4 of high-fat feeding. Our 
results, however, suggest that although a normal or reduced vascular 
resistance may be present in the obese dog, the initial stages of weight gain 
are associated w ith higher than normal FVR. As hterature regarding th is 
subject conflicts, further work in this area is warranted. Additionally, 
sympathetic activity may influence the vascular changes occurring during 
the initial period of weight gain, since the reduction in FVR to baseline 
levels as weight gain continued was prolonged in the intact limb. This
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suggests th a t sympathetic activity to the limb is instrum ental in 
m aintaining vascular resistance at a level higher than  th a t in vessels 
without sympathetic input. This too, w arrants further study.
In examination of the relationship of insulin and weight gain in these 
studies, we observed increasing in su lin  concentrations (as a  reflection of 
increasing insulin resistance) with weight gain. However, in s u lin  did not 
appear to correlate with arterial pressure or vascular resistance. This is 
consistent with the work of John Hall and his colleagues (1990; 1995), who 
could not identify an effect of chronic insulin infusion to increase arterial 
pressure in  lean or obese dogs. Although a correlation between in s u lin  and 
the cardiovascular parameters (HR, MAP, or FVR) was not evident, the 
significant increase in insulin preceded the return of FVR by 1 week in the 
DNX limb, but by 3 weeks in  the intact leg. This suggests th a t the 
increasing insulin concentration may work toward reductions in FVR and 
arterial pressure with weight gain were there not concurrent increased SNS 
activity in the obese. Previous findings th a t insulin infusion stimulates 
vasodilation (For review see Baron, 1994) and a reduction in arterial 
pressure (Hall et al., 1995) support this theory. Our findings suggest th a t 
autonomic activity in the intact hmb influences FVR during weight gain, 
and increased insulin levels may help prevent continued elevation in FVR 
in vessels th a t remain sensitive to its effects. Thus, sympathetic activity 
may be an  initiating factor predisposing to the development of hypertension 
associated w ith weight gain, and interaction with insulin may be important.
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However, we did not observe a difference in response to acute 
hyperinsulinemia between lean and obese dogs in the HIEC portions of our 
studies, nor were there differences in the response to hyperinsulinemia in 
the DNX and intact limbs.
A recent study identified renal sympathetic activity as a primary 
cause of hypertension in obesity (Kassab et al., 1994). In th a t study, 
bilateral renal denervation greatly attenuated the development of 
hypertension with overfeeding. Thus, although sympathetic renal 
mechanisms appear to be a primary factor involved in the development of 
obesity-related hypertension (Kassab et al., 1994), our study suggests that 
peripheral vascular effects of increased sympathetic activity may also be 
important in initiating the development of hypertension, prior to 
measurable changes in arterial pressure. These vascular changes may play 
a pivotal role in the series of events leading to hypertension in the obese. 
They are not likely, however, to be working alone, and w arrant further 
study.
Study 2: Cardiovascular parameters following NOS inhibition with 
LNA.
This study of canine cardiovascular function and stabilization 
following nitric oxide inhibition indicates th a t MAP, heart rate (HR) and 
femoral vascular resistance (FVR) are altered by administration of L-nitro- 
arginine. Also, the data suggest tha t the cardiovascular response to NOS 
inhibition differs between lean and obese dogs. Finally, once acclimated to
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NOS inhibition, cardiovascular param eters remain stable for the time 
period required to perform the hyperinsulinémie euglycemic clamp 
procedures described in our primary experiments.
In this experiment, acute nitric oxide synthase in h ib ition  with LNA 
sign ific a n t ly  increased MAP, which is consistent with previous f in d in gs by 
Eisner et al., 1992. As in the Eisner study, a s ig n ific a n t  reduction in heart 
rate occurred following LNA treatm ent in our animals, bu t this response 
was significantly reduced in the obese. In addition, the obese dogs had a 
significantly lower FVR response to LNA. The obese a n im a ls  in both the 
LNA-time course and the LNA-HIEC studies failed to show a significant 
change in FVR following LNA administration. However, a  significant FVR 
response to LNA was evident in the lean dogs, suggesting greater NOS 
activity compared to the obese. This observation is consistent with the 
previous work in essential hypertensives, who exhibit reduced vascular 
relaxation (Panza et al., 1993a, b). The reduction in vascular reactivity in 
this population is thought to involve abnormahties of the NOS pathway 
(Panza et al., 1990 and 1993b). However, it is not due to reduced 
availabihty of the natural substrate for NO synthesis (Panza et al., 1993a), 
and is not isolated to a specific defect of endothehal cell muscarinic 
receptors (Panza et al., 1994) or a single signal transduction pathway 
(Panza et al., 1995). Thus, although data are growing to describe the 
mechanisms through which reduced vascular response to NOS inhibition 
occurs in a population with physiologic changes similar to tha t of the obese
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(essential hypertensives), the pathways remain obscure. The reduced 
vascular response to NOS inhibition in the obese could reflect a defect in 
NO synthesis, release or diffusion of NO to vascular smooth muscle.
In addition to the finding th a t after initial changes in MAP, HR and 
FVR cardiovascular param eters stabilize following LNA administration, 
this study suggests th a t obesity is a  disorder of altered activity of the nitric 
oxide system. The obese animals of this study exhibited a reduced 
cardiovascular response to NOS inhibition. Also, the vascular response to 
NOS inhibition may be influenced by sympathetic nervous system activity, 
since the denervated and intact limb FVR response to LNA adm inistration 
differed in the lean dogs. Additionally, since the FVR response to NOS 
inhibition differed in lean and obese dogs, this could be a pathway 
mediating the development of hypertension with weight gain.
Studies 3 and 4: The HIEC, alone and following NOS inhibition.
In these studies examining the interaction of NOS, in su lin  and 
sympathetic activity, baseline insulin levels of the obese animals were 
greater than  the lean. This suggests reduced in s u lin  sensitivity in the over­
weight dogs, reflected as higher insulin levels. The finding of higher glucose 
infusion rates (GIR) during hyperinsulinémie euglycemia in the lean 
a n im a ls  also supports a  difference in insulin sensitivity between the weight 
groups (i.e. the lean are more sensitive to insulin-stimulated glucose 
disposal, thus require higher exogenous glucose infusion to m aintain 
euglycemia). These observations are consistent with previous f in d in g s  of
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hyperinsulinemia and/or reduced response to a  glucose tolerance test in the 
obese, reflecting resistance to insulin stimulated glucose disposal (Rocchini 
et al., 1987, 1989 and 1996; T ruett et al., 1996).
When hyperinsulinémie euglycemia was performed concurrent with 
NOS inhibition (LNA-HIEC study), no difference in GIR between the lean 
and obese animals was observed. Thus, NOS activity appears to influence 
insulin sensitivity in the canine. This fin d in g  contradicts those of Swislocki 
et al. (1995), who report s im ila r  glucose tolerance in  response to oral glucose 
tolerance tests in  controls and ra ts  a d m in is te re d  L-NAME i n  their drinking 
w ater. However, our data coincide with a study by Petrie et al. (1996), who 
report a  positive relationship between basal vascular NO production and 
insulin sensitivity in humans. In th a t study, individuals who were 
relatively insensitive to insulin-mediated glucose uptake using the clamp 
method also exhibited decreases in basal endothehal NO production.
Although glucose infusion rate within each weight group did not 
differ between the HIEC and LNA-HIEC studies, the lean animals tended to 
require a lower infusion rate of glucose when the clamp procedure was 
performed following LNA administration. This suggests th a t NOS 
inhibition may have a greater effect on in s u l in  sensitivity in normal 
compared to obese dogs. Two mechanism through which a reduction in 
insulin sensitivity may have occurred in the lean versus the obese dogs in 
our studies are:
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1) A greater increase in vascular resistance following LNA in  the 
lean animals caused a greater reduction in blood flow in this 
group. This reduction in flow decreased insulin dehvery to 
tissues, thereby reducing insulin stim ulated glucose disposal and 
insulin sensitivity of the lean animals.
2) If insulin's effect to reduce vascular tone and stimulate glucose 
uptake is mediated partly through nitric oxide activity (Chen and 
Messina, 1996; Baron, 1996), reduced NOS activity in the obese 
a n im a ls  would cause a baseline in su lin  resistance in this weight 
group. The lean animals, having greater baseline NOS activity 
would be more sensitive to insulin stimulation. If NOS was 
inhibited in both lean and obese a n im a ls , the change in insulin 
sensitivity between studies with and without NOS inhibition 
should be larger in the lean animals (since they should have 
greater baseline NOS activity). Thus, the influence of blocking 
nitric oxide on insulin’s abihty to stimulate glucose disposal 
should be more severely affected in the lean a n im a ls
In  support of mechanism number 1, insulin resistant subjects [obese 
in our study] are known to have a reduced vascular response to NO blockade 
(Panza et al., 1993a and b [in essential hypertensives]; Petrie et al., 1996). 
Thus, if vascular NOS activity is greater in the lean insulin sensitive dogs, 
there may have been a greater effect of NOS inhibition to reduce tissue 
perfusion in this group. The larger increase in FVR (lower flow) of the lean
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dogs may have resulted in a  reduction in insulin delivery, and a tendency 
toward reduced insulin sensitivity during the LNA-HIEC study. Skeletal 
muscle blood flow is known to modulate insulin-mediated glucose uptake 
(Baron et al., 1994). Thus, differences in tissue perfusion could have 
affected insulin sensitivity (as reflected by GIR) in these studies. In  the 
obese dogs, with reduced baseline NOS activity, the vasculature may have 
been less affected by NOS inhibition. Thus, insulin delivery (resultant firom 
changes in blood flow/FVR) may not have been as greatly altered in the 
obese dogs during h y p e r in s u lin e m ia  in LNA-HIEC study. Thus, in s u lin  
sensitivity would not appear to diffe r  between the HIEC and LNA-HIEC 
studies in the obese (as observed in our dogs). In  the lean animals of the 
LNA-HIEC study, the effects of LNA to increase vascular resistance (reduce 
flow) may have been greater than  in the obese. This lower flow in the lean 
a n im a ls  of the LNA Study may have resulted in reduced glucose disposal 
(seen as increased glucose infusion rate of the lean, compared to the HIEC 
study alone). Thus, the difference in glucose infusion rates between lean 
and obese dogs of the HIEC study would no longer be evident in the LNA- 
HIEC study. The findings of Baron and his colleagues (1995), suggest th a t 
reduced skeletal muscle perfusion contributes to insulin resistance induced 
by L-NMMA in rats. In addition, the work of Bergman and his colleagues 
suggests th a t delayed in s u lin  delivery to tissues an important factor in the 
insulin pathway responsible for the insulin resistant state (Yang et al.,
1989; Ader and Bergman, 1994), and is thus somewhat flow dependent.
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Thus, the insulin sensitivity results of our HIEC and LNA-HIEC studies 
could possibly reflect differing tissue perfusion.
The finding of reduced insulin sensitivity mainly in the lean dogs 
during the LNA-HIEC study also supports the second hypothesized 
mechanism of NOS-insulin interaction (NOS-mediated insulin activity 
mediates insulin sensitivity/glucose uptake). There is a large body of 
evidence supporting the fact that insulin-mediated vasodilation is nitric 
oxide dependent (Steinberg et al., 1994; Scherrer, et al., 1994) and the 
degree of vasodilation is proportional to insulin sensitivity (For review see 
Baron, 1996). In  obese humans with and without NIDDM, a recent study 
found a 40-50% reduction in endothelium-dependent vasodilation under 
basal conditions, as well as a marked impairment of insulin’s physiologic 
abihty to enhance this response (Steinberg et al., 1996). The lean animals 
of our study exhibited a greater increase in FVR w ith LNA adm inistration 
than  observed in the obese (Study 2 of these experiments; the LNA- 
cardiovascular stabihzation study). This suggests higher NOS activity in 
the lean versus obese dogs in the basal state. Thus, insulin (if mediated 
through NO activation) should have caused a greater effect on glucose 
disposal in the lean animals, as observed in the HIEC study. Also, if basal 
NO activity is increased in the lean, baseline insulin sensitivity should also 
be higher th an  in the obese. This was the case in the lean anim als of our 
studies, who had increased insulin sensitivity compared to the obese dogs of 
our studies (based upon higher basal insulin levels and increased glucose
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infusion rates required to maintain euglycemia during hyperinsulinemia). 
These data suggest tha t insulin action may be mediated by nitric oxide.
Also, NOS inhibition appears to have a greater effect on insulin sensitivity 
in lean versus obese dogs, possibly due to greater nitric oxide activity in 
lean individuals.
In  the HIEC and LNA-HIEC studies, MAP was not significantly 
affected by acute hyperinsulinemia, in either the lean or obese dogs. This 
finding is consistent with data of Hall et al., 1995, who did not find 
significant elevations in MAP with chronic insulin infusion in normal or 
obese dogs. Interestingly however, the change in MAP observed in response 
to hyperinsulinemia when NOS was concurrently inhibited (LNA-HIEC 
study) varied shghtly between the lean and obese. In this study, 
hyperinsulinemia tended to reduce MAP in the lean animals, whereas MAP 
in the obese animals was shghtly increased. Although these differences 
were not significant in our small group of animals, further study is 
warranted.
Although MAP increased shghtly in the obese and shghtly decreased 
in the lean foUowing hyperinsulinemia during the LNA-HIEC study, neither 
the femoral vascular resistance or HR was significantly influenced by 
hyperinsulinemia alone (HIEC) or concurrent w ith NOS inhibition (LNA- 
HIEC). However, in the lean animals a shght reduction in FVR was 
observed when insulin was infused foUowing LNA administration. This was 
not observed in the obese. Also, the obese dogs exhibited a shght increase in
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HR during insulin infusion in the LNA study. This increase in HR suggests 
an  increase in cardiac output (CO) occurred with insulin infusion, as 
previously reported (for review see Baron, 1994). In the presence of an 
inappropriate vascular response in  the obese dogs however, this increase in 
CO may have led to the increase in  obese MAP. In the lean group, who had 
a  more appropriate reduction in FVR (though not significant) in response to 
an  increase in CO, MAP remained unchanged. This hypothesis cannot be 
proven firom our data however, since cardiac output was not measured in 
our studies.
Since increases in MAP reflect changes in systemic vascular 
resistance, cardiac output, or blood volume/renal mechanisms (Guyton,
1991), one cannot fail to mention other mechanisms through which the 
shght increase in MAP observed in the obese during NOS inhibition and 
insulin infusion may have developed. Increases in vascular resistance may 
have occurred in unmeasured portions of the circulatory system (other than 
the femoral arteries) or renal fluid retention may have precipitated 
increases in plasma volume and cardiac output. Alternatively, a direct 
change in cardiac inotropic function may have taken place, increasing 
stroke volume and cardiac output (CO =stroke volume . HR) and 
precipitating the pressure elevation observed in the obese dogs during the 
LNA-HIEC study. However, neither renal function nor cardiac output were 
measured in these experiments.
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Although the data do not prove tha t cardiac output increased with 
insulin infusion, and the cardiovascular changes discussed above did not 
reach significance, basehne data collected during these studies support the 
hypothesis th a t abnormal vascular responses were present in  the obese 
anim als. Prior to manipulation with insulin, the HR of the obese dogs in 
the LNA-EŒEC study was greater than th a t of the lean anim als However, 
although FVR is lower in the obese group, the obese dog MAP is shghtly 
higher than the lean. Thus, prior to insulin administration, the peripheral 
vascular response to the increased heart rate in the obese animals was not 
adequate to compensate for the assumed higher cardiac output (CO=stroke 
volume . HR) of the obese animals. Thus, infusion of insulin may have 
further increased cardiac output, and with inadequate peripheral vascular 
response in the obese, MAP increased. As mentioned above, CO=SV.HR, 
and changes in  muscular efficiency of the heart can occur which may negate 
a rise in CO w ith a concurrent rise in HR (Guyton, 1991). Thus, 
inappropriate vascular response to an increase in CO induced by insulin 
may have resulted in the increase in MAP observed in the obese group.
Since we did not measure cardiac output, we cannot prove th a t the higher 
baseline HR of the obese was associated with increased CO, nor th a t insulin 
increased CO during hyperinsulinemia.
Though an  unlikely mechanism, MAP may have increased during 
acute hyperinsulinemia and concurrent NOS inhibition via renal 
mechanisms. Nitric oxide inhibition has been shown to increase renal
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vascular resistance and reduce renal blood/plasma flow in dogs (Eisner et 
al., 1992; Majid et al., 1993), reducing sodium excretion (Majid et al., 1993). 
Additionally, nitric oxide-induced changes in the renin-angiotensin system 
are reported, but are not as clear (Eisner e t al., 1992; Salazar et al., 1992; 
Schnackenberg et al., 1997; Sigmon et al., 1992). LNA-induced changes in 
renal function may have led to reduced sodium and w ater excretion in the 
animals of the LNA-HIEC study. Additional exogenous infusion of insulin 
and glucose during the clamp procedure may have compounded fluid 
changes occurring with LNA administration. Since insulin is known to have 
anti-natriuretic effects (DeFronzo, 1976, Rocchini et al 1989b), the obese are 
reported to have a reduced natriuretic response to volume expansion (West 
e t al., 1992), and insulin resistant hypertensive dogs may have increased 
renal sensitivity to NOS inhibition (Martinez et al., 1993), performing the 
clamp procedure with concurrent NOS inhibition may have changed renal 
fluid handling enough to increase MAP (via volume expansion) in the obese 
but not the lean dogs. Total body water and renal function were not 
measured in our studies, so these hypotheses are only speculation. Renal 
regulation of arterial pressure is a  more chronic method of pressure 
regulation. Thus, significant volume expansion (with associated increases 
in cardiac output and MAP) would be unlikely in such a short protocol 
(approximately 2hr). Additionally, average quantity of fluid (insulin and 
glucose infusions) administered to the obese dogs in the LNA-HIEC study
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was approximately 60 ml, which would be unlikely to cause significant, 
volume expansion.
Thus these studies suggest that interaction between insulin and 
nitric oxide may influence cardiovascular responses to weight gain. The 
nitric oxide system is important for the lean and obese response to insulin, 
and may be an important mechanism influencing insulin sensitivity. 
Although the results did not reach significance, differences in the insulin- 
nitric oxide relationship in the vasculature of the obese may occur, with a 
trend toward elevations in arterial pressure during acute hyperinsulinemia. 
However, the mechanism through which arterial pressure increases in the 
obese when insulin is infused during NOS inhibition remains obscure.
The small number of animals used in these studies, and the large 
variation in response may have overshadowed the abihty to identify small 
significant differences (especially since unadjusted p-values suggest a trend 
toward increased MAP and HR in the obese). This area deserves further 
study, since this alteration may be important in the arterial pressure 
response to weight gain as MAP tended to increase in the obese but 
decrease in the lean.
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CHAPTERS: CONCLUSIONS
The studies described herein suggest tha t in  the initial stages of 
overfeeding, there is increase in FVR, which then decreases to normal 
levels. The changes in FVR appear to be influenced by sympathetic activity, 
as the return  to baseline FVR was delayed in the limb retaining normal 
sympathetic innervation. Interaction of in su lin  w ith the vascular responses 
to weight gain does not appear significant, since correlation was not evident 
between insulin levels and vascular resistance.
The primary studies also provided interesting data about the 
NOS/insulin/SNS relationship. Lean and obese dogs respond differently to 
nitric oxide synthase inhibition: the obese exhibited a  reduced 
cardiovascular response to LNA administration (Study 2). As we 
hypothesized, SNS activity may be an important mediator (inhibitor) of NO 
activity, since the denervated limbs of the lean dogs showed a greater 
increase in FVR following NOS inhibition. In addition, this SNS/NO 
interaction may be abnormal in the obese, since the response of the DNX 
limb of the obese dogs was lower than  in the lean. We speculate th a t higher 
sympathetic activity in the obese may reduce peripheral NOS activity in 
this population, and reduce NOS-mediated vascular relaxation. Further 
examination of the nitric oxide/SNS interaction is warranted in the search 
for the mechanisms involved in the development of hypertension in the 
obese.
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Contrary to our hypothesis th a t NOS-mediated vascular response to 
insulin is abnormal in the obese, these studies did not identify a significant 
difference in cardiovascular response to hyperinsulinémie euglycemia 
between lean and obese dogs, when performed alone or in concert with nitric 
oxide inhibition. However, the trend toward increasing MAP with insulin 
infusion and concurrent NOS inhibition in the obese suggests th a t changes 
in the insulin-NO relationship may occur in the obese, predisposing to 
elevated arteria l pressure. Thus, further study, using a  larger sample size, 
is warranted to clarify changes in nitric oxide and insulin responses of the 
obese.
Another interesting finding of these studies is th a t NO activity 
influences insulin sensitivity in lean animals, with NOS inhibition resulting 
in a more ‘resistant’ state. This ‘resistance’ may involve a greater effect of 
NOS inhibition to reduce blood flow in the lean thereby altering insulin 
delivery to tissues, or may occur via reduced NOS-mediated insulin 
stimulated glucose disposal. Increases in SNS activity reported to occur in 
the obese may be a  mechanism mediating this reduction in NOS activity, 
and thus indirectly influence insulin sensitivity.
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